Clinical trial NCT05497557
Conditions: Healthy Volunteers
Keywords: Healthy volunteers Sotorasib AMG 510 Omeprazole
Sponsor: Amgen
Start date: 2022-07-14; Completion date: 2022-09-08
Enrollment: 16 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
The primary objective of the study is to evaluate the effects of omeprazole (a proton-pump inhibitor) and an acidic beverage (Coca-Cola) on sotorasib pharmacokinetics (PK) when administered orally in healthy volunteers.

Detailed description:

Arms: arm 1: None
Interventions: intervention 1: Omeprazole intervention 2: Sotorasib
Intervention descriptions: intervention 1: Omeprazole will be administered as an oral capsule. intervention 2: Sotorasib will be administered as an oral tablet.

Protocol documents:
Prot_000.pdf: 
Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 1 of 69 
Internal Use Only Medical and Scientific Affairs 
Protocol 
An Open-label Study to Evaluate the Impact of Omeprazole, 
A Proton Pump Inhibitor, on the Pharmacokinetics of Sotorasib 
Coadministered with an Acidic Beverage in Healthy Volunteers 
Protocol Status:  Final 
Protocol Date:  18 May 2022 
Original Protocol 
Investigational Product:  Sotorasib (AMG 510) 
Amgen Protocol Reference Number:  20220024 
Labcorp Drug Development Study Number:  8493285 
Sponsor: 
Amgen Inc. 
One Amgen Center Drive 
Thousand Oaks, California 91320 
USA 
This protocol was developed, reviewed, and approved in accordance with Labcorp’s 
standard operating procedures. This format and content of this protocol is aligned with 
Good Clinical Practice: Consolidated Guidance (ICH E6). 
NCT Number: NCT05497557
This NCT number has been applied to the document for
purposes of posting on Clinicaltrials.gov


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 2 of 69 
Internal Use Only Medical and Scientific Affairs 
Confidentiality Notice 
This document contains confidential information of Amgen Inc. 
This document must not be disclosed to anyone other than the site study staffs and 
members of the Institutional Review Board/Independent Ethics Committee/Institutional 
Scientific Review Board or equivalent. 
The information in this document cannot be used for any purpose other than the 
evaluation or conduct of the clinical investigation without the prior written consent of 
Amgen Inc. 
If you have questions regarding how this document may be used or shared, call the 
Amgen Medical Information number: US sites, 1- 800-77-AMGEN; Canadian sites, 
1-866-50-AMGEN; Amgen’s general number in the US, 1-805-447-1000. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 3 of 69 
Internal Use Only Medical and Scientific Affairs 
INVESTIGATOR AGREEMENT 
I have read the protocol entitled “An Open-label Study to Evaluate the Impact of Omeprazole, a 
Proton Pump Inhibitor, on the Pharmacokinetics of Sotorasib Coadministered with an Acidic 
Beverage in Healthy Volunteers” and agree to conduct the study as described herein. 
I agree to comply with the International Council for Harmonisation (ICH) Tripartite Guideline 
on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable national or regional 
regulations/guidelines.  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Amgen Inc. 
 
_______________________________ 
Signature 
 
_______________________________ 
____________________________ 
Name of Investigator  
Date (DD Month YYYY) 
 
_______________________________ 
Title and Role of Investigator 
 
_______________________________ 
Institution Name 
 
_______________________________ 
Address and Telephone Number of Institution 
_______________________________________ 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 4 of 69 
Internal Use Only Medical and Scientific Affairs 
STUDY IDENTIFICATION 
Sponsor 
Amgen Inc. 
One Amgen Center Drive 
Thousand Oaks, California 91320 
Sponsor’s Study Contact 
, PhD 
Director, Clinical Pharmacology 
Amgen Inc. 
One Amgen Center Drive 
Thousand Oaks, California 91320 
Tel:
Email
Medical Monitor 
, MD, PhD 
Medical Director 
Labcorp Drug Development 
3301 Kinsman Boulevard 
Madison, Wisconsin 53704 
Tel (Office): 
Tel (after hours):
Email:
Sponsor’s Study Manager 
 
Global Early Clinical Development Manager 
Amgen Inc. 
One Amgen Center Drive 
Thousand Oaks, California 91320 
Tel:
Email:
Labcorp Project Manager 
 
3402 Kinsman Boulevard 
Madison, Wisconsin 53704 
Tel:
Email:
Statistician 
, MS 
Senior Biostatistician 
Labcorp Drug Development 
3301 Kinsman Boulevard  
Madison, Wisconsin 53704 
Tel:
Email:
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 5 of 69 
Internal Use Only Medical and Scientific Affairs 
SYNOPSIS 
Title of study: An Open-label Study to Evaluate the Impact of Omeprazole, a Proton Pump 
Inhibitor, on the Pharmacokinetics of Sotorasib Coadministered with an Acidic Beverage in 
Healthy Volunteers 
Objectives:  
The primary objective of the study is: 
 
to evaluate the effects of omeprazole (a proton-pump inhibitor) and an acidic 
beverage (Coca-Cola) on sotorasib pharmacokinetics (PK) when administered orally 
in healthy volunteers. 
The secondary objective of the study is: 
 
to evaluate the safety and tolerability of sotorasib when coadministered with 
omeprazole and an acidic beverage in healthy subjects. 
Study design: 
This will be a Phase 1, single-center (United States), open-label, fixed sequence study to 
investigate the effect of coadministration of omeprazole with an acidic beverage on the PK of 
sotorasib in healthy male and female subjects. After informed consent is obtained, potential 
subjects will be screened to assess their eligibility to enter the study within 28 days prior to the 
first dose administration. Subjects will be admitted into the Clinical Research Unit (CRU) on 
Day -1 and be confined to the CRU until discharge/end of study (EOS) on Day 11. 
Subjects will receive a single dose of 960 mg sotorasib with 240 mL of water on Day 1, daily 
doses of 40 mg omeprazole with 240 mL of water on Days 4 to 8, and omeprazole and 
sotorasib with 240 mL of an acidic beverage on Day 9. 
Number of subjects: 
Up to 14 subjects will be enrolled to ensure that 12 subjects complete the study. 
Diagnosis and main criteria for inclusion: 
Healthy male subjects or female subjects of nonchildbearing potential, 18 to 60 years of age 
(inclusive), and body mass index of 18 to 30 kg/m2 (inclusive). 
Investigational products, dose, and mode of administration: 
Amgen Investigational Medicinal Product: 960 mg sotorasib (8 x 120 mg tablets) 
Amgen Non-Investigational Medicinal Product: 40 mg omeprazole delayed release capsule 
 
Day 1: 960 mg sotorasib administered orally with 240 mL of water after an overnight 
fast of at least 10 hours 
 
Days 4 to 8: 40 mg omeprazole (delayed release capsule) administered orally with 
240 mL of water once daily after an overnight fast of at least 10 hours 
 
Day 9: 40 mg omeprazole (delayed release capsule) followed by 960 mg sotorasib 
administered orally within 5 minutes with 240 mL of an acidic beverage after an 
overnight fast of at least 10 hours 
Duration of subject participation in the study: 
Planned Screening duration: approximately 4 weeks. 
Planned study duration (Screening to EOS): approximately 5.5 weeks.  


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 6 of 69 
Internal Use Only Medical and Scientific Affairs 
Primary endpoints: 
The primary endpoints for this study are sotorasib PK parameters on Days 1 and 9: maximum 
observed plasma concentration (Cmax), area under the plasma concentration-time curve from 
time zero to infinity (AUCinf), and area under the plasma concentration-time curve from time 
zero to time of last quantifiable concentration (AUClast). 
Secondary endpoints: 
The secondary endpoints for this study are adverse events, clinical laboratory tests, 12-lead 
electrocardiograms, and vital signs. 
Statistical methods: 
The primary PK parameters are Cmax, AUClast, and AUCinf for sotorasib on Days 1 and 9. A 
linear mixed-effects model will be used to analyze log-transformed primary PK parameters. 
The model assumes fixed effect for treatment and a random effect for subject. Geometric mean 
ratios for Cmax and AUC values and associated 90 confidence intervals (Test/Reference) will 
be estimated. The “Reference” treatment for PK analysis will be sotorasib administered alone 
with water, while the “Test” treatment will be omeprazole coadministered with sotorasib and 
an acidic beverage. 
 
The number and percentage of subjects reporting any adverse events will be tabulated by 
Medical Dictionary for Regulatory Activities system organ class and preferred term. Tables of 
fatal adverse events, serious adverse events, adverse events leading to withdrawal from 
investigational product or other protocol-required therapies, and significant treatment-
emergent adverse events will also be provided. Subject-level data may be provided instead of 
tables if the subject incidence is low. Endpoints for clinical laboratory tests, 
electrocardiograms, and vital signs will be summarized. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 7 of 69 
Internal Use Only Medical and Scientific Affairs 
TABLE OF CONTENTS 
INVESTIGATOR AGREEMENT.............................................................................................3 
STUDY IDENTIFICATION .....................................................................................................4 
SYNOPSIS .................................................................................................................................5 
TABLE OF CONTENTS ...........................................................................................................7 
LIST OF TABLES AND FIGURES........................................................................................10 
LIST OF ABBREVIATIONS ..................................................................................................11 
1. 
INTRODUCTION ...........................................................................................................13 
1.1. 
Background ............................................................................................................13 
1.2. 
Pharmacokinetics ...................................................................................................15 
1.3. 
Study Rationale ......................................................................................................16 
1.4. 
Benefit-risk Assessment.........................................................................................17 
1.4.1. 
Therapeutic Context .....................................................................................17 
1.4.1.1. 
Key Benefits.......................................................................................17 
1.4.1.2. 
Risks ...................................................................................................17 
2. 
OBJECTIVES AND ENDPOINTS .................................................................................18 
2.1. 
Objectives ..............................................................................................................18 
2.2. 
Endpoints ...............................................................................................................19 
2.2.1. 
Primary Endpoints .......................................................................................19 
2.2.2. 
Secondary Endpoints ...................................................................................19 
3. 
INVESTIGATIONAL PLAN ..........................................................................................19 
3.1. 
Overall Study Design and Plan ..............................................................................19 
3.2. 
Discussion of Study Design ...................................................................................20 
3.3. 
Selection of Doses in the Study .............................................................................21 
4. 
SELECTION OF STUDY POPULATION .....................................................................21 
4.1. 
Inclusion Criteria ...................................................................................................21 
4.2. 
Exclusion Criteria ..................................................................................................21 
4.3. 
Screen Failures and Rescreening ...........................................................................24 
4.4. 
Subject Number and Identification ........................................................................24 
4.5. 
Subject Withdrawal and Replacement ...................................................................24 
4.6. 
Study Termination .................................................................................................25 
4.7. 
Discontinuation of Study Treatment ......................................................................25 
5. 
STUDY TREATMENTS .................................................................................................26 
5.1. 
Investigational Product and Non-Investigational Products ....................................26 
5.2. 
Treatment Overdose ...............................................................................................28 
5.3. 
Medical Devices.....................................................................................................28 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 8 of 69 
Internal Use Only Medical and Scientific Affairs 
5.4. 
Product Complaints ................................................................................................28 
5.5. 
Randomization .......................................................................................................28 
5.6. 
Blinding..................................................................................................................28 
5.7. 
Treatment Compliance ...........................................................................................28 
5.8. 
Drug Accountability...............................................................................................29 
6. 
CONCOMITANT THERAPIES AND OTHER RESTRICTIONS ................................29 
6.1. 
Concomitant Therapies ..........................................................................................29 
6.2. 
Diet .........................................................................................................................29 
6.3. 
Smoking .................................................................................................................30 
6.4. 
Exercise ..................................................................................................................30 
6.5. 
Blood Donation ......................................................................................................30 
7. 
STUDY ASSESSMENTS AND PROCEDURES ...........................................................30 
7.1. 
Pharmacokinetic Assessments ...............................................................................31 
7.1.1. 
Pharmacokinetic Blood Sample Collection and Processing ........................31 
7.1.2. 
Analytical Methodology ..............................................................................31 
7.2. 
Safety and Tolerability Assessments .....................................................................31 
7.2.1. 
Adverse Events and Serious Adverse Events: Time Period and Frequency 
for Collecting and Reporting Safety Event Information ..............................31 
7.2.2. 
Clinical Laboratory Evaluations ..................................................................34 
7.2.3. 
Vital Signs ....................................................................................................34 
7.2.4. 
12-Lead Electrocardiogram .........................................................................35 
7.2.5. 
Physical Examination...................................................................................35 
8. 
SAMPLE SIZE AND DATA ANALYSIS ......................................................................35 
8.1. 
Determination of Sample Size ...............................................................................35 
8.2. 
Analysis Populations ..............................................................................................35 
8.2.1. 
Pharmacokinetic Population ........................................................................35 
8.2.2. 
Safety Population .........................................................................................36 
8.3. 
Pharmacokinetic Analyses .....................................................................................36 
8.4. 
Safety Analysis ......................................................................................................36 
8.5. 
Interim Analysis .....................................................................................................36 
9. 
REFERENCES ................................................................................................................36 
10. APPENDICES .................................................................................................................39 
Appendix 1: Safety Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting of Adverse Events and Serious Adverse Events ..........40 
Appendix 2: Clinical Laboratory Evaluations ...................................................................50 
Appendix 3: Total Blood Volume......................................................................................52 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 9 of 69 
Internal Use Only Medical and Scientific Affairs 
Appendix 4: Contraception Requirements .........................................................................53 
Appendix 5: Collection of Pregnancy and Lactation Information .....................................54 
Appendix 6: Regulatory, Ethical, and Study Oversight Considerations ............................58 
Appendix 7: Hepatotoxicity Stopping Rules: Suggested Actions and Follow-up 
Assessments ...........................................................................................................63 
Appendix 8: Schedule of Assessments ..............................................................................67 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 10 of 69 
Internal Use Only Medical and Scientific Affairs 
LIST OF TABLES AND FIGURES 
Table 1: 
Investigational Products and Non-Investigational Products ......................27 
Table 2: 
Conditions for Withholding and/or Permanent Discontinuation of Amgen 
Investigational Product and Other Protocol-required Therapies Due to Potential 
Hepatotoxicity ..............................................................................................................61 
  
Figure 1: 
Study Schematic.........................................................................................20 
Figure 2:  
Sample Serious Adverse Event Report Form ............................................45 
Figure 3:  
Pregnancy Notification Form .....................................................................53 
Figure 4:  
Lactation Notification Form ......................................................................54 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 11 of 69 
Internal Use Only Medical and Scientific Affairs 
LIST OF ABBREVIATIONS 
Abbreviation Definition 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
AV 
atrioventricular 
AUC 
area under the plasma concentration-time curve 
AUC0-24h 
area under the plasma concentration-time curve from time zero to 
24 hours postdose 
AUCinf 
area under the plasma concentration-time curve from time zero to 
infinity 
AUClast 
area under the plasma concentration-time curve from time zero to time 
of last quantifiable concentration 
BDC 
bile duct cannulated 
CFR 
Code of Federal Regulations 
Cmax 
maximum observed plasma concentration 
CRU 
Clinical Research Unit 
CTCAE 
Common Terminology Criteria for Adverse Events 
CV 
coefficient of variation 
CYP 
cytochrome P450 
DILI 
drug-induced liver injury 
ECG 
electrocardiogram 
eCRF 
electronic Case Report Form 
EDC 
electronic data capture 
EOS 
end of study 
FSH 
follicle-stimulating hormone 
GCP 
Good Clinical Practice 
HR 
heart rate 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Council for/Conference on Harmonisation 
ILD 
interstitial lung disease 
IMP 
investigational medicinal product 
INR 
international normalized ratio 
IRB 
Institutional Review Board 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 12 of 69 
Internal Use Only Medical and Scientific Affairs 
KRAS 
Kirsten rat sarcoma viral oncogene homolog (protein) 
KRAS 
Kirsten rat sarcoma viral oncogene homolog (gene) 
KRASG12C 
KRAS protein with a glycine to cysteine amino acid substitution at 
position 12 
KRAS 
p.G12C 
KRAS gene with a mutation resulting in a glycine to cysteine amino 
acid substitution at position 12  
MATE 
multidrug and toxic compound extrusion 
NSCLC 
non-small cell lung cancer 
OATP 
organic anion transporter 
P-gp 
P-glycoprotein 
PK 
pharmacokinetic(s) 
PPI 
proton pump inhibitor 
QD 
once daily 
QTcF 
QT interval corrected for heart rate based on the Fridericia correction 
TBL 
total bilirubin 
tmax 
time of the maximum observed concentration 
ULN 
upper limit of normal 
USPI 
United States Prescribing Information 
Vss 
volume of distribution at steady state 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 13 of 69 
Internal Use Only Medical and Scientific Affairs 
1. INTRODUCTION 
Refer to the Investigator’s Brochure (IB)1 for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event profile of the 
investigational medicinal product (IMP). 
1.1. 
Background 
Investigational Medicinal Product 
The role of Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations in human 
cancers has been known for decades;2 however, no anticancer therapies targeting KRAS 
mutations have been successfully developed. Thus, an unmet need exists for therapies that can 
specifically target cancers driven by KRAS mutations. Recent progress in the field suggests that 
1 mutant version of KRAS, KRAS p.G12C, which encodes the KRASG12C protein, might be 
tractable for small-molecule inhibition through a covalent interaction with the cysteine.3,4,5 
KRAS p.G12C mutation is a frequent mutation found in approximately 13 of lung 
adenocarcinoma (nonsquamous, non-small cell lung cancer [NSCLC]), 3 of colorectal cancer, 
and 1 to 2 of numerous other solid tumors.6,7,8 Sotorasib forms a specific covalent bond with 
the cysteine of KRASG12C, irreversibly locking the protein in an inactive conformation that 
cripples oncogenic signaling.5 As inactivation of KRAS has been demonstrated to inhibit cell 
growth and/or promote apoptosis selectively in tumor cells expressing KRAS mutations,9,10,11,3,4 
sotorasib may provide a therapeutic benefit for patients with KRAS p.G12C-driven cancers. 
The metabolism and excretion of [14C]-sotorasib were evaluated in noncannulated male or 
female rats as well as in bile duct cannulated (BDC) male rats after a single oral dose of sotorasib 
(60 mg/kg). Overall, the data indicated that sotorasib was readily absorbed after an oral dose to 
noncannulated male and female rats and BDC male rats, underwent extensive biotransformation, 
and was eliminated primarily by nonenzymatic conjugation and metabolic clearance; 
[14C]-sotorasib-derived radioactivity was excreted primarily through biliary and fecal pathways. 
Biotransformation of sotorasib was mediated primarily by nonenzymatic glutathione 
conjugation, oxidation, and to a lesser extent, reduction, and dealkylation. Secondary sotorasib 
metabolism was substantive and included amide hydrolysis, cysteine-conjugate cleavage, 
N-acetylation, methylation, glucuronidation, and sulfonation. Biotransformation of sotorasib 
through primary glutathione conjugation was major and accounted for up to approximately 
21 to 33 of the dose from intact male and female rats, respectively, and up to approximately 
41 of the dose in male BDC rats. Sotorasib metabolites originating from primary oxidation 
account for up to approximately 20 of the dose in noncannulated rats and for approximately 
10 of the dose in BDC rats. Reduction of the sotorasib acrolein moiety account for up to 
approximately 10 of the dose in noncannulated male and female rats and approximately 2.7 
of the dose in BDC rats, whereas dealkylation at the piperazine moiety accounted for 
approximately 10 to 13 of the dose in noncannulated rats and for approximately 6 of the 
dose in BDC rats. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 14 of 69 
Internal Use Only Medical and Scientific Affairs 
The metabolism and excretion of [14C]-sotorasib were evaluated in noncannulated male and 
female dogs after a single oral (500 mg/kg) dose of sotorasib. Overall, [14C]-sotorasib-derived 
radioactivity was minimally absorbed and was eliminated predominantly as unchanged sotorasib 
in feces following a single 500 mg/kg dose to male or female dogs. 
Eight sotorasib clinical studies (20170543, 20190009, 20190135, 20190147, 20190172, 
20190288, 20190436, and 20190442) are currently ongoing in subjects with KRAS 
p.G12C-mutated tumors. In addition, a number of studies in healthy volunteers have explored the 
pharmacokinetics (PK) of sotorasib, including assessments of mass-balance, food-effect, and 
various drug-drug interactions. 
Study 20170543 is an ongoing Phase 1/2, open-label, nonrandomized study evaluating the safety, 
tolerability, PK, pharmacodynamics, and efficacy of sotorasib in subjects with KRAS 
p.G12C-mutated NSCLC, colorectal cancer, and other solid tumors. As of 01 December 2020, 
456 subjects have been treated with sotorasib monotherapy across all doses (dose range: 180 to 
960 mg) and tumor types in the ongoing Phase 1 and Phase 2 treatment cohorts. This includes 
359 subjects who were treated with the sotorasib dose of 960 mg once daily (QD) (fasted) for all 
tumor types. 
For the combination therapy cohorts, as of the data cutoff date (06 July 2020), a total of 
11 subjects with NSCLC were treated with sotorasib in combination with pembrolizumab in 
Part 1c/2c of Study 20170543. As of the data cutoff date (12 July 2021), a total of 41 subjects 
with KRAS p.G12C-mutated advanced solid tumors were treated with sotorasib in combination 
with trametinib in Study 20190135 Subprotocol A. As of the data cutoff date (12 July 2021), 
a total of 33 subjects with KRAS p.G12C-mutated advanced NSCLC were treated with sotorasib 
in combination with afatinib in Study 20190135 Subprotocol D. As of the data cutoff date 
(12 July 2021), 44 subjects with KRAS p.G12C-mutated advanced solid tumors were treated with 
sotorasib and 39 subjects were treated with panitumumab in Study 20190135 Subprotocol H. 
A summary of completed and ongoing clinical studies for sotorasib is provided in the IB 
(Tables 6-1, 6-2, and 6-3).1 In the United States and several other countries, sotorasib (960 mg 
daily) is currently approved for the treatment of adult patients with KRAS p.G12C-mutated 
locally advanced or metastatic NSCLC who have received at least 1 prior systemic therapy. 
Non-Investigational Medicinal Product 
Omeprazole is a proton pump inhibitor (PPI) indicated for the treatment of duodenal and gastric 
ulcers, heartburn and other symptoms associated with gastroesophageal reflux disease, 
maintenance of healing of erosive esophagitis, and long-term treatment of pathological 
hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas, and 
systemic mastocytosis). Omeprazole inhibits gastric acid secretion and thereby increases the pH 
of the gastric environment, which may alter the absorption of some drugs with pH-dependent 
solubility and cause safety and efficacy concerns.  Please refer to the United States Prescribing 
Information (USPI) for Prilosec (omeprazole) capsules for additional information.12 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 15 of 69 
Internal Use Only Medical and Scientific Affairs 
1.2. 
Pharmacokinetics 
The PK of sotorasib have been characterized in healthy subjects and in subjects with KRAS 
p.G12C-mutated solid tumors, including NSCLC. Sotorasib exhibited nonlinear, time-dependent, 
PK over the dose range of 180 to 960 mg (0.19 to 1 times the approved recommended dosage) 
QD with similar systemic exposure (ie, area under the plasma concentration-time curve [AUC] 
from time zero to 24 hours postdose [AUC0-24h] and maximum observed plasma concentration 
[Cmax]) across doses at steady state. Sotorasib systemic exposure was comparable between 
film-coated tablets and film-coated tablets predispersed in water administered under fasted 
conditions. Sotorasib plasma concentrations reached steady state within 22 days. No 
accumulation was observed after repeat sotorasib dosages with a mean accumulation ratio of 
0.56 (coefficient of variation [CV]: 59). 
Absorption 
The median time of the maximum observed concentration (tmax) is 1 hour. 
Effect of Food 
When 960 mg sotorasib was administered with a high-fat, high-calorie meal (containing 
approximately 800 to 1000 calories with 150, 250, and 500 to 600 calories from protein, 
carbohydrate, and fat, respectively) in patients, sotorasib AUC0-24h increased by 25 compared 
to administration under fasted conditions. 
Distribution 
The sotorasib mean apparent volume of distribution at steady state (Vss) is 211 L (CV: 135). 
In vitro, sotorasib plasma protein binding is 89. 
Elimination 
The sotorasib mean terminal elimination half-life is 5 hours (standard deviation: 2). At 960 mg 
sotorasib QD, the sotorasib steady-state apparent clearance is 26.2 L/hr (CV: 76). 
Metabolism 
The main metabolic pathways of sotorasib are nonenzymatic conjugation and oxidative 
metabolism with cytochrome P450 (CYP)3As. 
Excretion 
After a single dose of radiolabeled sotorasib, 74 of the dose was recovered in feces (53 
unchanged) and 6 in urine (1 unchanged). 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 16 of 69 
Internal Use Only Medical and Scientific Affairs 
Specific Populations 
No clinically meaningful differences in the PK of sotorasib were observed based on age (28 to 
86 years), sex, race (White, Black, and Asian), body weight (36.8 to 157.9 kg), line of therapy, 
Eastern Cooperative Oncology Group (0, 1), mild and moderate renal impairment (estimated 
glomerular filtration rate:  30 mL/min/1.73 m2), or mild hepatic impairment (aspartate 
aminotransferase [AST] or alanine aminotransferase [ALT]  2.5 x upper limit of normal [ULN] 
or total bilirubin  1.5 x ULN). The effect of severe renal impairment or moderate to severe 
hepatic impairment on sotorasib PK has not been studied. Study 20200326 is currently ongoing 
to evaluate the PK of sotorasib in subjects with moderate or severe hepatic impairment. 
Drug-drug Interaction Studies 
Interactions of sotorasib with digoxin (P-glycoprotein [P-gp] substrate), metformin (multidrug 
and toxic compound extrusion [MATE]1 and MATE2-K substrate), itraconazole (CYP3A4 and 
P-gp inhibitor), rifampin (organic anion transporter [OATP] 1B1/1B3 inhibitors and CYP3A4 
inducer), omeprazole (PPI), famotidine (histamine-2 receptor antagonist), and midazolam 
(CYP3A4 substrate) are summarized in the IB (Table 6-3).1 Overall, these results suggest 
sotorasib may be taken safely with sensitive MATE1/2K substrates, CYP2D6 substrates, strong 
CYP3A4/P-gp inhibitors, and strong OATP1B1/1B3 inhibitors. However, exposures of P-gp and 
sensitive CYP3A4 substrates may be altered. 
Coadministration of PPIs (such as omeprazole), histamine-2 receptor antagonists, and strong 
CYP3A4 inducers may lead to decreased sotorasib exposure. 
1.3. 
Study Rationale 
The purpose of this study is to evaluate the effects of omeprazole, a PPI, on sotorasib PK when 
administered orally with an acidic beverage (Coca-Cola) and to evaluate the safety and 
tolerability of sotorasib when coadministered with omeprazole and an acidic beverage in healthy 
subjects. 
The concomitant use of sotorasib and acid-reducing agents was shown to decrease sotorasib 
exposures. Based on results from Study 20190320,1 geometric least-square mean ratios 
(test/reference) of sotorasib area under the plasma concentration-time curve from time zero to 
infinity (AUCinf) and Cmax were 0.582 and 0.431, respectively, when comparing sotorasib 
administered with omeprazole (test) and sotorasib administered alone (reference) in the fasted 
state. In Study 20200199,1 geometric least-square mean ratios of sotorasib AUCinf and Cmax were 
0.622 and 0.654, respectively, when comparing sotorasib coadministered with famotidine (test) 
and sotorasib alone (reference) under fed conditions. Geometric least-square mean ratios of 
sotorasib AUCinf and Cmax were 0.430 and 0.349, respectively, when comparing sotorasib 
coadministered with omeprazole (test) and sotorasib alone (reference) under fed conditions. 
These results suggest that concomitant administration of sotorasib with acid-reducing agents 
should be avoided. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 17 of 69 
Internal Use Only Medical and Scientific Affairs 
The rationale for this study is to see if temporarily lowering gastric pH by adding a glass of an 
acidic beverage could reduce the extent of the interaction between sotorasib and concomitantly 
administered PPIs. Coca-Cola is the acidic beverage chosen for this study and has a pH of 
approximately 2.5 that can alter the acidity in the gastric environment and mitigate the impact of 
acid-reducing agents on the exposures of several compounds.13,14,15,16  
1.4. 
Benefit-risk Assessment 
The following benefit-risk assessment supports the conduct of this clinical study. Refer to the IB1 
for more information. 
1.4.1. 
Therapeutic Context 
1.4.1.1. 
Key Benefits 
Healthy subjects in the current study will not receive any health benefit (beyond that of an 
assessment of their medical status) from participating in the study. 
1.4.1.2. 
Risks 
To limit the risk of excessive exposure to healthy subjects in the current study, subjects will 
receive a single oral dose of 960 mg sotorasib administered as 8 x 120 mg tablets on Day 1, and 
960 mg sotorasib in combination with 40 mg omeprazole and an acidic beverage on Day 9 
(details provided in Section 3.3). 
Safety monitoring: During the study, subjects will be administered all investigational product 
doses by site staff and will be instructed not to crush, chew, or split the sotorasib tablets or 
omeprazole when taking the dose under the supervision of the site staff. Safety assessments 
throughout the study include adverse event monitoring, electrocardiograms (ECGs), physical 
examination, vital signs, and clinical laboratory evaluations. 
Risks of Sotorasib 
Based on sotorasib clinical trials experience, adverse drug reactions with sotorasib include 
diarrhea, nausea, fatigue, vomiting, abdominal pain, increased liver enzymes, and interstitial lung 
disease (ILD)/pneumonitis. Based on nonclinical toxicity studies of sotorasib, potential safety 
concerns to be monitored in clinical studies of sotorasib include renal toxicity, anemia, and 
leukocytosis. Clinical signs and symptoms of these toxicities observed in clinical and nonclinical 
studies, along with relevant laboratory parameters, will be monitored during the study to ensure 
subjects’ safety. 
Abnormal Liver Function Tests 
Abnormal liver function tests (increased AST and increased ALT) have been observed in 
oncology subjects receiving sotorasib therapy. The events of abnormal liver function blood tests 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 18 of 69 
Internal Use Only Medical and Scientific Affairs 
generally resolved in subjects upon interruption of treatment.  The risk mitigation plan consists 
of monitoring liver enzymes, with regular measurement of AST, ALT, alkaline phosphatase, and 
bilirubin to be performed. Specific eligibility for sotorasib, including baseline liver function, are 
provided in Section 4. 
Interstitial Lung Disease/Pneumonitis 
Interstitial lung disease/pneumonitis has occurred in patients treated with sotorasib with prior 
exposure to immunotherapy or radiotherapy. Incidence of ILD in clinical trials was 
approximately 0.8. All events were serious and Grade 3 or 4 at onset, and 2 subjects 
discontinued sotorasib because of ILD/pneumonitis. During the study, subjects should be 
monitored for new or worsening pulmonary symptoms. At any grade, immediately withhold 
sotorasib for suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is 
confirmed. 
As of 11 January 2022, no clinically meaningful sotorasib-related renal toxicity, anemia, 
leukocytosis, thyroid dysfunction, or splenomegaly has been observed. More detailed 
information about the key safety information of sotorasib, including a list of adverse drug 
reactions, may be found in the sotorasib IB and USPI.1,17 
Non-investigational Medicinal Product Risks 
Commonly reported adverse events for omeprazole include headache, abdominal pain, nausea, 
diarrhea, vomiting, and flatulence. Please refer to the package insert for commonly reported 
adverse events for omeprazole.12 
2. OBJECTIVES AND ENDPOINTS 
2.1. 
Objectives 
The primary objective of the study is: 
 to evaluate the effects of omeprazole (a PPI) and an acidic beverage on sotorasib PK 
when administered orally in healthy volunteers. 
The secondary objective of the study is: 
 to evaluate safety and tolerability of sotorasib when coadministered with omeprazole 
and an acidic beverage in healthy subjects. 
2.2. 
Endpoints 
2.2.1. 
Primary Endpoints  
The primary endpoints of the study are sotorasib PK parameters on Days 1 and 9: 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 19 of 69 
Internal Use Only Medical and Scientific Affairs 
 Cmax 
 AUCinf 
 area under the plasma concentration‑time curve from time zero to time of last 
quantifiable concentration (AUClast) 
2.2.2. 
Secondary Endpoints 
The secondary endpoints of the study are: 
 adverse events 
 clinical laboratory tests 
 12-lead ECGs 
 vital signs. 
3. INVESTIGATIONAL PLAN 
3.1. 
Overall Study Design and Plan 
This will be a Phase 1, single-center (United States), open-label, fixed sequence study to 
investigate the effect of coadministration of omeprazole with an acidic beverage on the PK of 
sotorasib in healthy male and healthy female subjects. Up to 14 subjects will be enrolled to 
ensure that 12 subjects complete the study.  All subjects will receive each of the following 
treatments: 
 Day 1: 960 mg sotorasib (8 x 120 mg tablets) administered orally with 240 mL of water 
after an overnight fast of at least 10 hours 
 Days 4 to 8: 40 mg omeprazole (delayed release capsule) administered orally with 
240 mL of water QD after an overnight fast of at least 10 hours 
 Day 9: 40 mg omeprazole (delayed release capsule) followed by 960 mg sotorasib 
(8 x 120 mg tablets) administered orally within 5 minutes with 240 mL of an acidic 
beverageafter an overnight fast of at least 10 hours. 
An overview of the study design is shown in Figure 1. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 20 of 69 
Internal Use Only Medical and Scientific Affairs 
Figure 1: 
Study Schematic 
 
Potential subjects will be screened to assess their eligibility to enter the study within 28 days 
prior to the first dose administration. Subjects will be admitted into the Clinical Research Unit 
(CRU) on Day -1 and be confined to the CRU until discharge/end of study (EOS) on Day 11. 
The total duration of study participation for each subject (from Screening through EOS visit) is 
anticipated to be approximately 5.5 weeks. 
The start of the study is defined as the date the first enrolled subject signs an Informed Consent 
Form (ICF). The point of enrollment occurs at the time of subject number allocation. The end of 
the study is defined as the date of the last subject’s last assessment (scheduled or unscheduled). 
A Schedule of Assessments is presented in Appendix 8. 
3.2. 
Discussion of Study Design 
The fixed sequence design used in this study is typical for interaction studies where a relatively 
small number of subjects are required. This study will be open-label because the study endpoints 
are not considered subjective. 
Omeprazole is a well-established PPI and has been used in clinical drug interaction studies.  
The proposed regimen for omeprazole in this study is to take omeprazole alone QD for 5 days 
followed by coadministration of omeprazole and sotorasib plus an acidic beverage. An acidic 
beverage is expected to temporarily lower gastric pH. The 5-day lead-in period is to maximize 
the antisecretory effect because the inhibition of acid secretion increases with repeated QD 
dosing, reaching a plateau after 4 days.12 
Conducting the study in healthy subjects mitigates the potential confounding effects of the 
disease state and concomitant medications. 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 21 of 69 
Internal Use Only Medical and Scientific Affairs 
3.3. 
Selection of Doses in the Study 
The approved dose level of sotorasib is 960 mg.14 There have been 6 clinical studies in healthy 
subjects where sotorasib has been administered at dose levels up to 960 mg and was well 
tolerated across the studies. In addition, there have been no dose-limiting toxicities observed 
with sotorasib monotherapy at 960 mg in subjects with advanced tumors with the 
KRAS p.G612C mutation. Please refer to the IB1 for more information. 
In this study, the 40 mg omeprazole dose will be administered orally. This is a clinically 
recommended dose level and a dose level used to evaluate clinical drug interactions. 
4. SELECTION OF STUDY POPULATION 
4.1. 
Inclusion Criteria 
Subjects must satisfy all of the following criteria prior to enrollment unless otherwise stated: 
1. Subject has provided informed consent before initiation of any study-specific 
activities/procedures. 
2. Healthy male or nonchildbearing female subjects, between 18 and 60 years of age 
(inclusive) at the time of Screening. 
3. In good health, determined by no clinically significant findings from medical history, 
physical examination, 12-lead ECGs, vital signs measurements, and clinical laboratory 
evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert’s 
syndrome based on total and direct bilirubin] is not acceptable) as assessed by the 
Investigator (or designee). 
4. Body mass index between 18 and 30 kg/m2 (inclusive) at the time of Screening. 
5. Females must be of nonchildbearing potential, defined as permanently sterile (ie, due to 
hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal 
(defined as at least 45 years of age with amenorrhea for 12 months without an alternative 
medical cause and follicle-stimulating hormone [FSH] level  40 mIU/mL). 
4.2. 
Exclusion Criteria 
Subjects will be excluded from the study if they satisfy any of the following criteria prior to 
enrollment unless otherwise stated: 
1. History or evidence, at Screening or Check-in, of clinically significant disorder, 
condition, or disease not otherwise excluded that, in the opinion of the Investigator (or 
designee), would pose a risk to subject safety or interfere with the study evaluation, 
procedures, or completion. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 22 of 69 
Internal Use Only Medical and Scientific Affairs 
2. History or evidence of clinically significant arrhythmia at Screening, including any 
clinically significant findings on the ECG taken at Check-in. 
3. A QT interval corrected for heart rate (HR) based on the Fridericia correction (QTcF) 
interval  450 msec in male subjects or  470 msec in female subjects or history/evidence 
of long QT syndrome; and/or PR interval  200 msec, second degree atrioventricular 
(AV) block or third degree AV block, at Screening or Check-in. Electrocardiograms will 
be taken as single ECGs.  If parameters are out-of-range, the site will collect 2 more 
ECGs and then calculate the mean to determine eligibility. 
4. Systolic blood pressure  140 mmHg or  90 mmHg, or diastolic blood pressure 
 90 mmHg, or HR  100 bpm, at Screening or Check-in. Subjects with out-of-range 
values that are not clinically significant (as determined by the Investigator) may have the 
test repeated once during Screening or Check-in (within 1 hour of original assessment) 
and the subject may be enrolled if a repeated value is within normal range. 
5. History suggestive of achlorhydria, esophageal (including esophageal spasm, 
esophagitis), gastric, or duodenal ulceration or bowel disease (including, but not limited 
to, peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn’s disease, or 
irritable bowel syndrome), or a history of gastrointestinal surgery other than 
uncomplicated appendectomy. 
6. Inability to swallow oral medication or history of malabsorption syndrome. 
7. History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other 
substance, unless approved by the Investigator (or designee) and in consultation with the 
Sponsor. 
8. Poor peripheral venous access. 
9. Estimated glomerular filtration rate less than 70 mL/min/1.73 m2 as calculated by the 
CKD-EPI Creatinine Equation18, at Screening or Check-in. Subjects with out-of-range 
values may have the test repeated once at the discretion of the Investigator. 
10. ALT or AST should be ULN at Screening or Check-in (for these parameters, a subject 
with out-of-range values may have the tests repeated once and the subject may be 
enrolled if the repeated values are ULN or if the repeated values above ULN are 
deemed not clinically significant by the Investigator [eg, 1.5 x ULN]). 
11. Positive hepatitis B or hepatitis C panel and/or positive human immunodeficiency virus 
test at Screening. Subjects whose results are compatible with prior immunity (vaccination 
or prior infection) may be included. 
12. Use of any over-the-counter or prescription medications within 30 days or 5 half-lives 
(whichever is longer) before enrollment, unless deemed acceptable by the Investigator (or 
designee) and in consultation with the Sponsor. 
a. Acetaminophen [paracetamol] (up to 2 g per day) for analgesia will be allowed. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 23 of 69 
Internal Use Only Medical and Scientific Affairs 
13. All herbal medicines (eg, St. John’s wort), vitamins, and supplements consumed by the 
subject within the 30 days prior to enrollment, unless deemed acceptable by the 
Investigator (or designee) and in consultation with the Sponsor. 
14. Consumption of foods and beverages containing poppy seeds, grapefruit, or Seville 
oranges within 7 days prior to Check-in.  
15. History of alcoholism or drug/chemical abuse within 1 year prior to Check-in. 
16. Alcohol consumption from 48 hours prior to Check-in. 
17. Regular alcohol consumption of  14 units per week for males and  7 units per week for 
females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz 
(150 mL) wine. 
18. Use of tobacco- or nicotine-containing products within 6 months prior to Check-in. 
19. Positive test for illicit drugs, cotinine (tobacco or nicotine use) at Screening or Check-in 
and/or alcohol use at Check-in only. 
20. Consumption of caffeine-containing foods and beverages within 48 hours prior to 
Check-in. 
21. Female subjects with a positive pregnancy test at Screening or Check-in. 
22. Female subjects lactating/breastfeeding or who plan to breastfeed during the study 
through 7 days after the EOS. 
23. Unwilling to adhere to contraceptive requirements through 7 days after the EOS (see  ).  
24. Unwilling to abstain from sperm donation through 7 days after the EOS (see ). 
25. Male subjects with a female partner of childbearing potential and not willing to inform 
his partner of his participation in this clinical study. 
26. Male subjects with a pregnant partner or partner planning to become pregnant who are 
unwilling to practice abstinence (refrain from heterosexual intercourse) or use 
contraception while the subject is on study through 7 days after the EOS. 
27. Subject has received a dose of an investigational drug within the past 30 days or 
5 half-lives, whichever is longer, prior to Check-in. 
28. Have previously completed or withdrawn from this study or any other study investigating 
sotorasib or have previously received the investigational product.  
29. Donation of blood from 90 days prior to Check-in, plasma from 2 weeks prior to 
Check-in, or platelets from 6 weeks prior to Check-in. 
30. Receipt of blood products within 2 months prior to Check-in.  
31. Unwilling to abide with study restrictions. 
32. Subjects who, in the opinion of the Investigator (or designee), should not participate in 
this study. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 24 of 69 
Internal Use Only Medical and Scientific Affairs 
33. Performed strenuous exercise, began a new exercise program, or participated in any 
unusually strenuous physical exertion within 7 days prior to Check-in. 
4.3. 
Screen Failures and Rescreening 
Screen failures are defined as subjects who consent to participate in the clinical study but are not 
subsequently enrolled in the study because they do not meet eligibility requirements. A minimal 
set of screen failure information will be collected that includes demography, screen failure 
details, eligibility criteria, medical history, prior therapies, and any serious adverse events. 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened only once.  
4.4. 
Subject Number and Identification 
Subjects will have a unique identification number used at Screening. Subjects will be assigned a 
subject number prior to the first dosing occasion. Assignment of subject numbers will be in 
ascending order and no numbers will be omitted (eg, Subjects 0101, 0102, 0103). Replacement 
subjects will be assigned a subject number corresponding to the number of the subject he/she is 
replacing plus 1000 (eg, Subject 1101 replaces Subject 0101). 
Subjects will be identified by subject number only on all study documentation. A list identifying 
the subjects by subject number will be kept in the Site Master File. 
4.5. 
Subject Withdrawal and Replacement 
A subject is free to withdraw from the study at any time. In addition, a subject will be withdrawn 
from dosing if any of the following criteria are met: 
 change in compliance with any inclusion/exclusion criterion that is clinically relevant and 
affects subject safety as determined by the Investigator (or designee) 
 noncompliance with the study restrictions that might affect subject safety or study 
assessments/objectives, as considered applicable by the Investigator (or designee) 
 occurrence of any Common Terminology Criteria for Adverse Events (CTCAE) v5.0 
Grade 3 adverse event 
 occurrence of Grade 2 adverse event considered by the Investigator (or designee) to be at 
least possibly related to sotorasib and, in the opinion of the Investigator (or designee), 
warrants subject withdrawal (eg, neuropathy, chronic diarrhea, etc) 
 any clinically relevant sign or symptom that, in the opinion of the Investigator (or 
designee), warrants subject withdrawal. 
If 2 or more subjects are withdrawn from the study due to adverse events that are considered by 
the Investigator to be at least possibly related to sotorasib or if there is 1 Grade 3 event, dosing 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 25 of 69 
Internal Use Only Medical and Scientific Affairs 
will be paused, and the Investigator and Sponsor will convene to review the data and determine 
the next step. 
If a subject is withdrawn from dosing, the Sponsor (or designee) will be notified and the date and 
reason(s) for the withdrawal will be documented in the subject’s electronic Case Report Form 
(eCRF). If a subject is withdrawn, efforts will be made to perform all EOS assessments, if 
possible (Appendix 8). Other procedures may be performed at the Investigator’s (or designee’s) 
and/or Sponsor’s discretion. If the subject is in-house, these procedures should be performed 
before the subject is discharged from the clinic. The Investigator (or designee) may also request 
that the subject return for an additional follow-up visit. All withdrawn subjects will be followed 
until resolution of all their adverse events, or until the unresolved adverse events are judged by 
the Investigator (or designee) to have stabilized. 
Subjects who are withdrawn for reasons not related to study drug may be replaced following 
discussion between the Investigator and the Sponsor. Subjects withdrawn as a result of adverse 
events/serious adverse events thought to be related to the study drug will generally not be 
replaced. 
4.6. 
Study Termination  
The Sponsor may stop the study or study site participation in the study for medical, safety, 
regulatory, administrative, or other reasons consistent with applicable laws, regulations, and 
Good Clinical Practice. Both the Sponsor and the Investigator reserve the right to terminate the 
Investigator's participation in the study according to the Clinical Trial Agreement. The 
Investigator is to notify the Institutional Review Board (IRB) in writing of the study's completion 
or early termination and send a copy of the notification to the Sponsor. The Sponsor reserves the 
unilateral right, at its sole discretion, to determine whether to supply investigational product and 
by what mechanism, after termination of the study.  
In addition, the study may be terminated by the Sponsor at any time and for any reason. If the 
Sponsor decides to terminate the study, they will inform the Investigator as soon as possible. 
4.7. 
Discontinuation of Study Treatment 
Subjects (or a legally acceptable representative) can decline to continue receiving investigational 
product and/or other protocol-required therapies or study procedures at any time during the study 
but continue participation in the study. If this occurs, the Investigator is to discuss with the 
subject the appropriate processes for discontinuation from investigational product or other 
protocol-required therapies and must discuss with the subject the possibilities for continuation of 
the Schedule of Assessments (Appendix 8) including different options of follow-up (eg, in 
person, by phone/mail, through family/friends, in correspondence/communication with other 
treating physicians, from the review of medical records) and collection of data, including 
endpoints, adverse events, serious adverse events, and must document this decision in the 
subject’s medical records. Subjects who have discontinued investigational product and/or other 
protocol-required therapies or study procedures should not be automatically removed from the 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 26 of 69 
Internal Use Only Medical and Scientific Affairs 
study. Whenever safe and feasible, it is imperative that subjects remain on study to ensure safety 
surveillance and/or collection of outcome data. 
Reasons for removal from protocol-required investigational product(s) or procedural assessments 
include any of the following: 
 Decision by the Sponsor 
 Lost to follow-up 
 Death 
 Protocol deviation 
 Noncompliance  
 Adverse events  
 Subject request 
 Pregnancy.  
5. STUDY TREATMENTS 
Study treatment is defined as any investigational product, non-investigational product, placebo, 
combination product, or medical device intended to be administered to a study subject according 
to the study protocol. 
Note that in several countries, investigational product and non-investigational product are 
referred to as IMP and non-IMP, respectively. 
5.1. 
Investigational Product and Non-Investigational Products 
The IMP will be supplied by the Sponsor. The Investigational Product Instruction Manual, a 
document external to this protocol, contains detailed information regarding the storage, 
preparation, destruction, and administration of the IMP shown in Table 1. 
The Investigator will commercially source the non-IMP shown in Table 1. The non-IMP will be 
stored according to the manufacturer’s instructions. 
All supplies of investigational product, both bulk and subject-specific, will be stored in 
accordance with the manufacturer’s instructions or pharmacy instructions. Until dispensed to the 
subjects, the investigational products will be stored at the study site in a location that is locked 
with restricted access. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 27 of 69 
Internal Use Only Medical and Scientific Affairs 
Table 1: 
Investigational Products and Non-Investigational Products 
Study Treatment 
Name 
Amgen Investigational 
Medicinal Product: 
 Sotorasib (AMG 510) 
Non-Amgen Investigational 
Medicinal Product: 
Omeprazole 
Unit Strength and 
Formulation 
120 mg tablet 
40 mg delayed release capsule 
Dosage Level 
960 mg (8 x 120 mg tablets) 
40 mg (1 x 40 mg capsule) 
Route of 
Administration 
Oral 
Oral 
Accountability 
The quantity administered, date 
administered, and lot number of 
investigational product are to be 
recorded on each subject's electronic 
Case Report Form.  
The quantity administered, date 
administered, and lot number of 
non-investigational product are to be 
recorded on each subject's electronic 
Case Report Form. 
Dosing Instructions 
The Investigator/designee will 
administer the treatment after the 
completion of all predose procedures. 
Day 1: Eight tablets will be 
administered with 8 ounces (240 mL) 
of water after an overnight fast of at 
least 10 hours. No food will be given 
for at least 4 hours postdose.  
Day 9: Omeprazole will be 
administered followed by 960 mg 
sotorasib within 5 minutes. 
Omeprazole and sotorasib will be 
taken with 8 ounces (240 mL) of an 
acidic beverage (Coca-Cola after 
an overnight fast of at least 10 hours. 
No food will be given for at least 
4 hours post sotorasib administration. 
The Investigator/designee will 
administer the treatment after the 
completion of all predose 
procedures. 
Days 4 to 8: One capsule will be 
administered with 8 ounces 
(240 mL) of water after an overnight 
fast of at least 10 hours. 
Day 9: Omeprazole will be 
administered followed by 960 mg 
sotorasib within 5 minutes. 
Omeprazole and sotorasib will be 
taken with 8 ounces (240 mL) of an 
acidic beverage (Coca-Cola) after 
an overnight fast of at least 10 hours. 
No food will be given for at least 4 
hours post sotorasib administration. 
Note: Only Coca-Cola will be consumed with omeprazole and sotorasib on Day 9. 
Except as part of the dose administration, subjects will restrict their consumption of water for 
1 hour prior to dosing and for 2 hours after dosing; at all other times during the study, subjects 
may consume water as desired. No food will be given for at least 4 hours post sotorasib 
administration. 
Subjects will be dosed while standing and will not be permitted to lie supine for 2 hours after 
administration of IMP and non-IMP, except as necessitated by the occurrence of an adverse 
event(s) and/or study procedures. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 28 of 69 
Internal Use Only Medical and Scientific Affairs 
5.2. 
Treatment Overdose 
The effects of overdose of sotorasib are not known. In case of overdose, consultation with the 
medical monitor is recommended for prompt reporting of clinically apparent or laboratory 
adverse events possibly related to over dosage, and to discuss further management of the subject. 
5.3. 
Medical Devices 
No investigational medical device(s) will be used in this study. Other non-investigational 
medical devices may be used in the conduct of this study as part of standard care. Non-Amgen 
non-investigational medical devices (eg, syringes, sterile needles) that are commercially 
available are not usually provided or reimbursed by the Sponsor (except, for example, if required 
by local regulation). The Investigator will be responsible for obtaining supplies of these devices. 
5.4. 
Product Complaints 
A product complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a 
drug(s) or device(s) after it is released for distribution to market or clinic by either (1) Sponsor or 
(2) distributors or partners for whom the Sponsor manufactures the material. This includes all 
components distributed with the drug, such as packaging drug containers, delivery systems, 
labeling, and inserts. This includes any IMP (sotorasib) and non-IMP (omeprazole) provisioned 
and/or repackaged/modified by the Sponsor. 
Any product complaint(s) associated with an IMP supplied by the Sponsor are to be reported 
according to the instructions provided in the Amgen Investigational Product Information Manual. 
5.5. 
Randomization 
This is a nonrandomized study. The study has a fixed treatment sequence.  
5.6. 
Blinding 
This is an open-label study. 
5.7. 
Treatment Compliance 
The following measures will be employed to ensure treatment compliance: 
 All doses of sotorasib and omeprazole will be administered under the supervision of 
suitably qualified study site staff. 
 Immediately after dose administration, visual inspection of the mouth and hands will be 
performed for each subject. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 29 of 69 
Internal Use Only Medical and Scientific Affairs 
 At each dosing occasion, a predose and postdose inventory of sotorasib and omeprazole 
will be performed.  
5.8. 
Drug Accountability 
The Investigator (or designee) will maintain an accurate record of the receipt of sotorasib tablets 
received. In addition, an accurate drug disposition record will be kept, specifying the amount 
dispensed to each subject and the date of dispensing. This drug accountability record will be 
available for inspection at any time. At the completion of the study, the original drug 
accountability record will be available for review by the Sponsor upon request. 
For each batch of unit doses, the empty used unit dose containers will be discarded upon 
satisfactory completion of the compliance and accountability procedures. Any unused assembled 
unit doses will be retained until completion of the study. 
At the completion of the study, all unused sotorasib tablets will be returned to the Sponsor, 
retained at the study site, or disposed of by the study site, per the Sponsor’s written instructions. 
Omeprazole will also be subject to accountability procedures, and the CRU staff will destroy 
unused supplies of omeprazole per the Sponsor’s written instructions. 
6. CONCOMITANT THERAPIES AND OTHER RESTRICTIONS 
6.1. 
Concomitant Therapies 
Subjects will refrain from use of any prescription or nonprescription medications/products during 
the study until the EOS visit, unless the Investigator (or designee) and/or Sponsor have given 
their prior consent. 
Paracetamol/acetaminophen (2 g/day) are acceptable concomitant medications. The 
administration of any other concomitant medications during the study is prohibited without prior 
approval of the Investigator (or designee), unless its use is deemed necessary for treatment of an 
adverse event/serious adverse event. Any medication taken by a subject during the course of the 
study and the reason for its use will be documented in the source data. 
6.2. 
Diet 
Subjects will be fasted overnight (at least 8 hours) before collection of blood samples for clinical 
laboratory evaluations. While confined at the study site, subjects will receive a standardized diet 
at scheduled times that do not conflict with other study-related activities. 
Refer to Section 5 and Table 1 for diet requirements/restrictions on applicable days of study 
treatment and/or PK assessments. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 30 of 69 
Internal Use Only Medical and Scientific Affairs 
Foods and beverages containing poppy seeds, grapefruit, or Seville oranges will not be allowed 
from 7 days prior to Check-in until EOS. 
Caffeine-containing foods and beverages will not be allowed from 48 hours before Check-in 
until the EOS visit, with the exception of the Day 9 visit (dosing plus an acidic beverage). 
Consumption of alcohol will not be permitted from 48 hours prior to Check-in until the EOS 
visit. 
6.3. 
Smoking 
Subjects will not be permitted to use tobacco- or nicotine-containing products within 6 months 
prior to Check-in until the EOS visit. 
6.4. 
Exercise 
Subjects are required to refrain from strenuous exercise from 7 days before Check-in until EOS. 
Subjects will otherwise maintain their normal level of physical activity during this time (ie, will 
not begin a new exercise program nor participate in any unusually strenuous physical exertion). 
6.5. 
Blood Donation 
Subjects are required to refrain from donation of blood from 90 days prior to Check-in, plasma 
from 2 weeks prior to Check-in, and platelets from 6 weeks prior to Check-in until 90 days after 
the EOS. 
7. STUDY ASSESSMENTS AND PROCEDURES 
Every effort will be made to schedule and perform the procedures as closely as possible to the 
nominal time, giving considerations to appropriate posture conditions, practical restrictions, and 
the other procedures to be performed at the same timepoint.  
The highest priority procedures will be performed closest to the nominal time. The order of 
priority for scheduling procedures around a timepoint is (in descending order of priority): 
 dosing 
 PK blood samples 
 safety assessments (ECGs will be scheduled before vital signs measurements) 
 any other procedures. 
Where activities at a given timepoint coincide, consideration must be given to ensure that the 
following order of activities is maintained: ECGs, vital signs, safety laboratory assessments, and 
assessment of adverse events and serious adverse events. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 31 of 69 
Internal Use Only Medical and Scientific Affairs 
7.1. 
Pharmacokinetic Assessments 
7.1.1. 
Pharmacokinetic Blood Sample Collection and Processing 
Blood samples (approximately 1 x 4 mL for sotorasib) will be collected by venipuncture or 
cannulation at the times indicated in the Schedule of Assessments in Appendix 8. Procedures for 
collection, processing, and shipping of PK blood samples will be detailed in a separate 
document. 
Any blood sample collected according to the Schedule of Assessments (Appendix 8) can be 
analyzed for any of the tests outlined in the protocol and for any tests necessary to minimize 
risks to study subjects. This includes testing to ensure analytical methods produce reliable and 
valid data throughout the course of the study. This can also include, but is not limited to, 
investigation of unexpected results, incurred sample reanalysis, and analyses for method transfer 
and comparability. 
7.1.2. 
Analytical Methodology 
Plasma concentrations of sotorasib will be determined using validated analytical procedures. 
Specifics of the analytical method will be provided in a separate document. 
7.2. 
Safety and Tolerability Assessments 
7.2.1. 
Adverse Events and Serious Adverse Events: Time Period and Frequency for 
Collecting and Reporting Safety Event Information 
Adverse event definitions, assignment of severity and causality, and procedures for reporting 
adverse events and serious adverse events are detailed in Appendix 1. 
The condition of each subject will be monitored from the time of signing the ICF to EOS. If an 
event is reported as beginning prior to signing of the ICF or occurs prior to initiation of study 
treatment on Day 1 and is assessed as not related to study procedures by the Investigator (or 
designee), the event will be recorded as subject medical history. If an event occurs after signing 
of the ICF but prior to initiation of study drug and the event is considered serious (regardless of 
causality to procedure), the event will be recorded as a serious adverse event. 
Any events occurring after study drug administration on Day 1 through EOS will be reported as 
adverse events. Subjects will be observed for any signs or symptoms and asked about their 
condition by open questioning, such as “How have you been feeling since you were last asked?”, 
at least once each day while resident at the study site and at each study visit. Subjects will also be 
encouraged to spontaneously report adverse events and serious adverse events occurring at any 
other time during the study. 
Adverse Events 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 32 of 69 
Internal Use Only Medical and Scientific Affairs 
The adverse event grading scale to be used in this study is described in Appendix 1. 
The Investigator is responsible for ensuring that all adverse events observed by the Investigator 
or reported by the subject (whether reported by the subject voluntarily or upon questioning or 
noted on physical examination) from the first dose of study drug through the EOS visit are 
recorded/reported using the appropriate eCRF. 
Serious Adverse Events 
The Investigator is responsible for ensuring that all serious adverse events observed by the 
Investigator or reported by the subject that occur after signing of the ICF through 30 days after 
the last dose of study treatment or the EOS visit (whichever is later) are reported using the 
appropriate eCRF and reported on the paper-based Serious Adverse Event Report Form 
(described in Appendix 1). 
All serious adverse events will be collected, recorded, and reported to the Sponsor within 
24 hours of the Investigator’s awareness of the event. The Investigator will submit any updated 
serious adverse event data to the Sponsor within 24 hours of it being available. 
Since the criteria for the CTCAE grading scale differs from the regulatory criteria for serious 
adverse events, if adverse events correspond to Grade 4 CTCAE toxicity grading scale criteria 
(eg, laboratory abnormality reported as Grade 4 without manifestation of life-threatening status), 
it will be left to the Investigator’s judgment to also report these abnormalities as serious adverse 
events. For any adverse event that applies to this situation, comprehensive documentation of the 
event’s severity must be recorded in the subject medical records. 
Serious Adverse Events After the Protocol-Required Reporting Period  
After EOS, there is no requirement to actively monitor study subjects after the study has ended 
with regards to study subjects treated by the Investigator. However, if the Investigator becomes 
aware of serious adverse events suspected to be related to investigational product, then these 
serious adverse events will be reported to the Sponsor within 24 hours following the 
Investigator’s awareness of the event. 
Serious adverse events reported outside of the protocol-required reporting period will be 
captured within the Sponsor’s safety database as clinical trial cases and handled accordingly 
based on the relationship to investigational product. 
If further safety-related data are needed to fulfill any regulatory reporting requirements for a 
reportable event, then additional information may need to be collected from the subject’s records 
after the subject ends the study. 
Method of Detecting Adverse Events and Serious Adverse Events  


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 33 of 69 
Internal Use Only Medical and Scientific Affairs 
Care will be taken not to introduce bias when detecting adverse events and/or serious adverse 
events. Open-ended and non-leading verbal questioning of the subject is the preferred method to 
inquire about adverse event occurrence. 
Follow-up of Adverse Events and Serious Adverse Events 
After the initial adverse event/serious adverse event report, the Investigator is required to 
proactively follow each subject at subsequent visits/contacts. All adverse events and serious 
adverse events will be followed, where possible, until resolution, stabilization, until the event is 
otherwise explained, or the subject is lost to follow-up. This will be completed at the 
Investigator’s (or designee’s) discretion. 
All new information for previously reported serious adverse events must be sent to Amgen 
within 24 hours following knowledge of the new information. If specifically requested, the 
Investigator may need to provide additional follow-up information, such as discharge summaries, 
medical records, or extracts from the medical records. Information provided about the serious 
adverse event must be consistent with that recorded on the eCRF. 
Regulatory Reporting Requirements for Serious Adverse Events 
If a subject is permanently withdrawn from protocol-required therapies because of a serious 
adverse event, this information must be submitted to the Sponsor. 
Prompt notification by the Investigator to the Sponsor of serious adverse events is essential so 
that legal obligations and ethical responsibilities towards the safety of subjects and the safety of a 
study treatment under clinical investigation are met. 
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation. The 
Sponsor will comply with country-specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRBs, and Investigators. 
Individual safety reports must be prepared for suspected unexpected serious adverse reactions 
according to local regulatory requirements and Sponsor policy and forwarded to Investigators as 
necessary. 
An Investigator who receives an individual safety report describing a serious adverse event or 
other specific safety information (eg, summary or listing of serious adverse events) from the 
Sponsor will file it along with the IB and will notify the IRB, if appropriate according to local 
requirements. 
Safety Monitoring Plan 
Subject safety will be routinely monitored as defined in the Sponsor’s safety surveillance and 
signal management processes. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 34 of 69 
Internal Use Only Medical and Scientific Affairs 
Pregnancy and Lactation 
Details of all pregnancies and/or lactation in female subjects and pregnancies in female partners 
of male subjects will be collected after the start of the study treatment until 7 days after EOS. 
If a pregnancy is reported, the Investigator is to inform Amgen within 24 hours of learning of the 
pregnancy and/or lactation and is to follow the procedures outlined in Appendix 5. Amgen 
Global Patient Safety will follow-up with the Investigator regarding additional information that 
may be requested. 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered serious adverse events. 
Further details regarding pregnancy and lactation are provided in Appendix 5. 
7.2.2. 
Clinical Laboratory Evaluations 
Blood and urine samples will be collected for clinical laboratory evaluations (including clinical 
chemistry, hematology, urinalysis, and serology) at the times indicated in the Schedule of 
Assessments in Appendix 8. Clinical laboratory evaluations are listed in Appendix 2. 
The Investigator is responsible for reviewing laboratory test results and recording any clinically 
relevant changes occurring during the study in the Case Report Form/eCRF. The Investigator 
must determine whether an abnormal value in an individual study subject represents a clinically 
significant change from the subject’s baseline values. In general, abnormal laboratory findings 
without clinical significance (based on the Investigator’s judgement) are not to be recorded as 
adverse events. However, laboratory value changes that require treatment or adjustment in 
current therapy are considered adverse events. Where applicable, clinical sequelae (not the 
laboratory abnormality) are to be recorded as the adverse event. Subjects who develop any 
laboratory abnormalities outside the reference range that are deemed clinically meaningful 
during the study period will have follow-up laboratory assessments once a week, or more 
frequently if deemed necessary, until the abnormalities have resolved or returned to within the 
reference range or to the subject’s baseline values. 
Subjects will be asked to provide urine samples for drugs of abuse screen and cotinine test, and 
will undergo an alcohol urine or breath test at the times indicated in the Schedule of Assessments 
in Appendix 8. For all female subjects, a pregnancy test and FSH screen for postmenopausal 
women will be performed at the times indicated in the Schedule of Assessments in Appendix 8. 
An Investigator (or designee) will perform a clinical assessment of all clinical laboratory data. 
7.2.3. 
Vital Signs 
Supine blood pressure, supine HR, respiratory rate, and oral body temperature will be assessed at 
the times indicated in the Schedule of Assessments in Appendix 8. Vital signs may also be 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 35 of 69 
Internal Use Only Medical and Scientific Affairs 
performed at other times if judged to be clinically appropriate or if the ongoing review of the 
data suggests a more detailed assessment of vital signs is required. 
All measurements will be performed singly and repeated once if outside the relevant clinical 
reference range. 
Subjects must be supine for at least 5 minutes before blood pressure and heart rate 
measurements. When vital signs are scheduled at the same time as blood draws, the blood draws 
will be obtained at the scheduled timepoint, and the vitals will be obtained as close to the 
scheduled blood draw as possible, but prior to the blood draw. 
7.2.4. 
12-Lead Electrocardiogram 
Resting 12-lead ECGs will be recorded after the subject has been supine and at rest for at least 
5 minutes at the times indicated in the Schedule of Assessments in Appendix 8. Single 12-lead 
ECGs will be repeated twice, and an average taken of the 3 readings, if either of the following 
criteria apply: 
 QTcF is 500 ms 
 QTcF change from the baseline (predose) is 60 ms. 
Additional 12-lead ECGs may be performed at other times if judged to be clinically appropriate 
or if the ongoing review of the data suggests a more detailed assessment of ECGs is required. 
The Investigator (or designee) will perform a clinical assessment of each 12-lead ECG. 
7.2.5. 
Physical Examination 
A full physical examination or symptom-directed physical examination will be performed at the 
timepoints specified in the Schedule of Assessments in Appendix 8. 
8. SAMPLE SIZE AND DATA ANALYSIS 
8.1. 
Determination of Sample Size 
Approximately 14 subjects will be enrolled in order that approximately 12 subjects complete the 
study. The sample size for this study was based upon precedent set by other PK studies of a 
similar nature and was not based on power calculations. 
8.2. 
Analysis Populations 
8.2.1. 
Pharmacokinetic Population 
The PK population will include all subjects who received at least 1 dose of sotorasib and have 
evaluable PK data. The PK population for the primary endpoint analysis will include all subjects 
who received both sotorasib, and sotorasib in combination with omeprazole and an acidic 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 36 of 69 
Internal Use Only Medical and Scientific Affairs 
beverage, and have evaluable PK data. A subject will be excluded from the PK summary 
statistics and statistical analysis if the subject has an adverse event of vomiting that occurs at or 
before 2 times median tmax or diarrhea within 24 hours of dosing. 
8.2.2. 
Safety Population 
The safety population will include all subjects who received at least 1 dose of sotorasib and have 
at least 1 postdose safety assessment. 
8.3. 
Pharmacokinetic Analyses 
The plasma PK parameters of sotorasib on Days 1 and 9 will be calculated using standard 
noncompartmental methods. 
The primary PK parameters are Cmax, AUCinf, and AUClast for sotorasib. A linear mixed-effects 
model will be used to analyze log-transformed primary PK parameters. The model will assume 
fixed effect for treatment and a random effect for subject. Geometric mean ratios for Cmax and 
AUC values and associated 90 confidence intervals (Test/Reference) will be estimated. The 
“Reference” treatment for PK analysis will be sotorasib administered alone with water, while the 
“Test” treatment will be omeprazole administered in combination with sotorasib and an acidic 
beverage. 
Additional parameters may be calculated. Specific details will be presented in the Statistical 
Analysis Plan for this study. 
8.4. 
Safety Analysis 
The number and percentage of subjects reporting any adverse events will be tabulated by 
Medical Dictionary for Regulatory Activities system organ class and preferred term. Tables of 
fatal adverse events, serious adverse events, adverse events leading to withdrawal from 
investigational product or other protocol-required therapies, and significant treatment-emergent 
adverse events will also be provided. Subject-level data may be provided instead of tables if the 
subject incidence is low. 
Endpoints for clinical laboratory tests, ECG, and vital signs will be summarized. 
8.5. 
Interim Analysis 
No interim analyses are planned for this study. 
9. REFERENCES 
1. Amgen. AMG 510 – Investigator’s Brochure. (Version 6.2). 25 February 2022. 
2. Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell 
Sci. 2016;129(7):1287-1292. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 37 of 69 
Internal Use Only Medical and Scientific Affairs 
3. Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS; from structural insights 
to mechanism-based design. Nat Rev Drug Discov. 2016;15(11):771-785. 
4. Patricelli MP, Janes MR, Li LS, et al. Selective inhibition of oncogenic KRAS output with 
small molecules targeting the inactive state. Cancer Discov. 2016;6:316-329. 
5. Canon J, Rex K, Saiki AY, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-
tumour immunity. Nature. 2019;575:217-223. 
6. The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision 
Medicine Through an International Consortium. Cancer Discov. 2017;7(8):818-831. 
7. Biernacka A, Tsongalis PD, Peterson JD, et al. The potential utility of re-mining results of 
somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 
2016;209(5):195-198. 
8. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations 
in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 
2009;205(12):858-862. 
9. Janes MR, Zhang J, Li LS, et al. Targeting KRAS mutant cancers with a covalent G12C-
specific inhibitor. Cell. 2018;172(3):578-589. 
10. McDonald ER, de Weck A, Schlabach MR, et al. Project DRIVE: A compendium of cancer 
dependencies and synthetic lethal relationships uncovered by large-scale deep RNAi 
screening. Cell. 2017;170(3):577-592. 
11. Xie C, Li Y, Li LL, et al. Identification of a new potent inhibitor targeting KRAS in non-
small cell lung cancer cells. Front Pharmacol. 2017;8:823. 
12. Prilosec (omeprazole) Prescribing Information. Wilmington, DE: AstraZeneca 
Pharmaceuticals LP. September 2012. 
13. Van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the 
absorption of erlotinib in patients with non-small cell lung cancer. J Clin Oncol. 2016 
Apr 20;34:1309-1314. 
14. van Seyen M, Colbers A, Abbink EJ, et al. Concomitant Intake of Coca-Cola to Manage the 
Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers. 
Clin Pharmacol Ther. 2019;106(5):1093-1098. doi:10.1002/cpt.1569. 
15. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of 
itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997 Jun;37(6):535-540. doi: 
10.1002/j.1552-4604.1997.tb04332.x. PMID: 9208361. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 38 of 69 
Internal Use Only Medical and Scientific Affairs 
16. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of 
ketoconazole. Antimicrob Agents Chemother. 1995 Aug;39(8):1671-1675. doi: 
10.1128/AAC.39.8.1671. PMID: 7486898; PMCID: PMC162805. 
17. Food and Drug Administration LUMAKRASTM (sotorasib) tablets prescribing information. 
Revised May 2021. Amgen. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf. 
18. Delgado, C. et al. A unifying approach for GFR estimation: recommendations of the NKF-
ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J. Am. 
Soc. Nephrol. 2021 Dec;32(12):2994-3015. doi: https://doi.org/10.1681/ASN.2021070988. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 39 of 69 
Internal Use Only Medical and Scientific Affairs 
10. APPENDICES 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 40 of 69 
Internal Use Only Medical and Scientific Affairs 
Appendix 1: Safety Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting of Adverse Events and Serious Adverse Events 
Definition of Adverse Event 
Adverse Event Definition 
 An adverse event is any untoward medical occurrence in a clinical study subject 
irrespective of a causal relationship with the study treatment.  
 Note: An adverse event can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or 
exacerbated) temporally associated with the use of a treatment, combination 
product, medical device, or procedure. 
 Note: Treatment-emergent adverse events will be defined in the Statistical Analysis 
Plan. 
Events Meeting the Adverse Event Definition 
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, electrocardiogram, radiological scans, vital signs 
measurements), including those that worsen from baseline, that are considered 
clinically significant in the medical and scientific judgment of the Investigator (ie, 
not related to progression of underlying disease). 
 Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
 New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study. 
 Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication. Overdose per se will not be reported as an 
adverse event/serious adverse event unless it is an intentional overdose taken with 
possible suicidal/self-harming intent. Such overdoses are to be reported regardless 
of sequelae. 
 “Lack of efficacy” or “failure of expected pharmacological action” per se will not 
be reported as an adverse event or serious adverse event. Such instances will be 
captured in the efficacy assessments. However, the signs, symptoms, and/or clinical 
sequelae resulting from lack of efficacy will be reported as adverse events or 
serious adverse events if they fulfill the definition of an adverse event or serious 
adverse event. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 41 of 69 
Internal Use Only Medical and Scientific Affairs 
Events NOT Meeting the Adverse Event Definition 
 Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE. 
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
 
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen. 
Definition of Serious Adverse Event 
A Serious Adverse Event is defined as any untoward medical occurrence that 
meets at least 1 of the following serious criteria: 
Results in death (fatal) 
Immediately life-threatening 
The term “life-threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe. For instance, 
drug-induced hepatitis that resolved without evidence of hepatic failure would not 
be considered life threatening even though drug-induced hepatitis can be fatal. 
Requires in-patient hospitalization or prolongation of existing hospitalization 
In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospitalization are an adverse event. If a complication prolongs hospitalization or 
fulfills any other serious criteria, the event is serious. When in doubt as to whether 
“hospitalization” occurred or was necessary, the adverse event is to be considered 
serious. Hospitalization for elective treatment of a pre-existing condition that did 
not worsen from baseline is not considered an adverse event. 
Results in persistent or significant disability/incapacity 
The term “disability” means a substantial disruption of a person’s ability to conduct 
normal life functions. This definition is not intended to include experiences of 
relatively minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which 
may interfere with or prevent everyday life functions but do not constitute a 
substantial disruption. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 42 of 69 
Internal Use Only Medical and Scientific Affairs 
Is a congenital anomaly/birth defect 
Other medically important serious event 
Medical or scientific judgment is to be exercised in deciding whether serious 
adverse event reporting is appropriate in other situations such as important medical 
events that may not be immediately life-threatening or result in death or 
hospitalization but may jeopardize the subject or may require medical or surgical 
intervention to prevent 1 of the other outcomes listed in the above definition. These 
events are typically to be considered serious. 
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug 
dependency or drug abuse. 
Recording Adverse Events and Serious Adverse Events 
Adverse Event and Serious Adverse Event Recording 
 When an adverse event or serious adverse event occurs, it is the responsibility of 
the Investigator to review all documentation (eg, hospital progress notes, 
laboratory, and diagnostics reports) related to the event. 
 The Investigator will then record all relevant adverse event/serious adverse event 
information in the Event electronic Case Report Form (eCRF). 
 The Investigator must assign the following adverse event attributes: 
o Adverse event diagnosis or syndrome(s), if known (if not known, signs or 
symptoms); 
o Dates of onset and resolution (if resolved); 
o Did the event start prior to first dose of investigational product; 
o Assessment of seriousness; 
o Severity (or toxicity defined below); 
o Assessment of relatedness to the investigational product(s) and/or study-
mandated procedures;  
o Action taken; and  
o Outcome of event. 
 If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the worst severity on the appropriate eCRF.  


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 43 of 69 
Internal Use Only Medical and Scientific Affairs 
 It is not acceptable for the Investigator to send photocopies of the subject’s medical 
records to the Sponsor in lieu of completion of the appropriate eCRF page. 
 If specifically requested, the Investigator may need to provide additional follow-up 
information, such as discharge summaries, medical records, or extracts from the 
medical records. In this case, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical records before 
submission to the Sponsor. 
 The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the adverse event/serious 
adverse event.  
Evaluating Adverse Events and Serious Adverse Events 
Assessment of Severity 
The Investigator will make an assessment of severity for each adverse event and 
serious adverse event reported during the study. The assessment of severity will be 
based on the Common Terminology Criteria for Adverse Events (CTCAE) grading 
scale. For the CTCAE grading scale version 5.0, refer to: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
Assessment of Causality 
 The Investigator is obligated to assess the relationship between investigational 
product(s), protocol-required therapy, and/or study-mandated procedure and each 
occurrence of each adverse event/serious adverse event. 
 Relatedness means that there are facts or reasons to support a relationship between 
investigational product and the event. 
 The Investigator will use clinical judgment to determine the relationship. 
 Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be considered and investigated. 
 The Investigator will also consult the Investigator’s Brochure and/or Product 
Information, for marketed products, in his/her assessment. 
 For each adverse event/serious adverse event, the Investigator must document in the 
medical notes that he/she has reviewed the adverse event/serious adverse event and 
has provided an assessment of causality. 
 There may be situations in which a serious adverse event has occurred and the 
Investigator has minimal information to include in the initial report. However, it is 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 44 of 69 
Internal Use Only Medical and Scientific Affairs 
very important that the Investigator always make an assessment of causality for 
every event before the initial transmission of the serious adverse event data. 
 The Investigator may change his/her opinion of causality in light of follow-up 
information and send a serious adverse event follow-up report with the updated 
causality assessment. 
 The causality assessment is 1 of the criteria used when determining regulatory 
reporting requirements. 
Follow-up of Adverse Event and Serious Adverse Event 
 The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the 
Sponsor to elucidate the nature and/or causality of the adverse event or serious 
adverse event as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health 
care professionals. 
 If a subject is permanently withdrawn from protocol-required therapies because of a 
serious adverse event, this information must be submitted to the Sponsor. 
 If a subject dies during participation in the study or during a recognized follow-up 
period, the Investigator will provide the Sponsor with a copy of any postmortem 
findings including histopathology. 
 New or updated information will be recorded in the originally completed eCRF. 
 The Investigator will submit any updated serious adverse event data to the Sponsor 
within 24 hours of receipt of the information. 
Reporting of Serious Adverse Event 
Serious Adverse Event Reporting via Paper Serious Adverse Event Report Form 
 Facsimile transmission of the Serious Adverse Event Report Form (see Figure 2) is 
the preferred method to transmit this information. 
 In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is acceptable with a copy of the Serious Adverse Event Report Form sent 
by overnight mail or courier service. 
 Initial notification via telephone does not replace the need for the Investigator to 
complete and sign the Serious Adverse Event Report Form within the designated 
reporting time frames. 
 Once the study has ended, serious event(s) suspected to be related to investigational 
product will be reported to Amgen if the Investigator becomes aware of a serious 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 45 of 69 
Internal Use Only Medical and Scientific Affairs 
adverse event. The Investigator should use the paper-based Serious Adverse Event 
Report Form to report the event. 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 46 of 69 
Internal Use Only Medical and Scientific Affairs 
Figure 2:  
Sample Serious Adverse Event Report Form 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 47 of 69 
Internal Use Only Medical and Scientific Affairs 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 48 of 69 
Internal Use Only Medical and Scientific Affairs 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 49 of 69 
Internal Use Only Medical and Scientific Affairs 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 50 of 69 
Internal Use Only Medical and Scientific Affairs 
Appendix 2: Clinical Laboratory Evaluations 
Clinical chemistry: 
Hematology: 
Urinalysis: 
Alanine aminotransferase 
Albumin 
Alkaline phosphatase 
Aspartate aminotransferase 
Blood urea nitrogen 
Calcium 
Chloride 
Cholesterol 
Creatinine 
Direct bilirubina  
Gamma-glutamyl transferase 
Glucose 
Indirect bilirubina 
Inorganic phosphate 
Magnesium 
Potassium 
Sodium 
Total bilirubina 
Total CO2 (measured as 
bicarbonate) 
Total creatine kinase 
Total protein 
Uric acid 
Hematocrit  
Hemoglobin 
Mean cell hemoglobin 
Mean cell hemoglobin 
concentration 
Mean cell volume 
Platelet count 
Red blood cell (RBC) count 
RBC distribution width 
White blood cell (WBC) count 
WBC differential: 
   Basophils 
   Eosinophils 
   Lymphocytes 
   Monocytes 
   Neutrophils 
 
Bilirubin 
Blood 
Color and appearance 
Glucose 
Ketones 
Leukocyte esterase 
Nitrite 
pH 
Protein 
Specific gravity 
Urobilinogen 
Microscopic examination (if 
protein, leukocyte esterase, 
nitrite, or blood is positive) 
Serologyb: 
Drug screenc: 
Hormone panel - females 
only: 
Anti-hepatitis B surface antibody 
Anti-hepatitis B core antibody 
Hepatitis B surface antigen 
Hepatitis C antibody 
Human immunodeficiency virus 
(HIV-1 and HIV-2) antibodies 
and p24 antigen 
Including but not limited to: 
Amphetamines/methamphetamin
es 
Barbiturates 
Benzodiazepines 
Cocaine (metabolite) 
Cotinine test 
Methadone 
Phencyclidine 
Opiates 
Tetrahydrocannabinol/ 
cannabinoids 
Tricyclic antidepressants 
Alcohol urine or alcohol breath 
test (Check-in only) 
 
Follicle-stimulating hormoneb 
(postmenopausal females only) 
Serum pregnancy test (human 
chorionic gonadotropin)d 
Urine pregnancy testd 
Other tests: 
International normalized ratio 
(INR)e 
Estimated glomerular filtration 
rate (eGFR)c,f 
Thyroid-stimulating hormoneg 
a Direct and indirect bilirubin will be analyzed if total bilirubin is elevated. 
b Only analyzed at Screening. 
c Only analyzed at Screening and Check-in. 
d Performed at Screening, Check-in, and at the end of study or if a subject is withdrawn early from the study. 
Performed in serum at Screening and in urine at all other times for all females. A positive urine pregnancy test will be 
confirmed with a serum pregnancy test. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 51 of 69 
Internal Use Only Medical and Scientific Affairs 
e International normalized ratio will be tested if hepatotoxicity is suspected, per guidelines presented in Appendix 7. 
f Calculated by the Modification of Diet in Renal Disease equation. 
g. Only analyzed at Screening, Check-in, and at end of study. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 52 of 69 
Internal Use Only Medical and Scientific Affairs 
Appendix 3: Total Blood Volume 
The following blood volumes will be withdrawn for each subject. 
 
Volume per blood 
sample (mL) 
Maximum number 
of blood samples 
Total amount of 
blood (mL) 
Clinical laboratory 
evaluations 
12.5 
4 
50.0 
Serology 
7.0 
1 
7.0 
Sotorasib 
pharmacokinetics 
4.0 
28 
112.0 
Total: 
169.0 
If extra blood samples are required, the maximum blood volume to be withdrawn per subject will 
not exceed 500 mL. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 53 of 69 
Internal Use Only Medical and Scientific Affairs 
Appendix 4: Contraception Requirements 
All subjects must receive pregnancy prevention counseling and be advised of the risk to the fetus 
if they conceive a child during treatment and for 7 days after the end of study (EOS) visit. 
Additional medications given during the study may alter the contraceptive requirements. The 
Investigator must discuss these contraceptive changes with the subject. 
Definitions  
Women of Childbearing Potential: premenopausal females who are anatomically and 
physiologically capable of becoming pregnant following menarche.  
Women of Nonchildbearing Potential: 
1. Surgically sterile: Females who are permanently sterile via hysterectomy, bilateral 
salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical 
records. Surgical sterilization to have occurred a minimum of 6 weeks, or at the 
Investigator’s discretion, prior to Screening.  
2. Postmenopausal: Females at least 45 years of age with amenorrhea for 12 months 
without an alternative medical reason with confirmatory follicle-stimulating hormone 
levels of  40 mIU/mL. The amenorrhea should not be induced by a medical condition 
such as anorexia nervosa, hypothyroid disease, or polycystic ovarian disease, or by 
extreme exercise. It should not be due to concomitant medications that may have induced 
the amenorrhea such as oral contraceptives, hormones, gonadotropin-releasing hormones, 
anti-estrogens, or selective estrogen receptor modulators.  
Fertile male: a male that is considered fertile after puberty.  
Infertile male: permanently sterile male via bilateral orchiectomy.  
Contraception Requirements 
Female Subjects: 
Only female subjects who are of nonchildbearing potential will be enrolled in the study and are 
not required to use contraception. 
Male Subjects:  
Male subjects with nonchildbearing female partners (as defined above) are not required to use 
contraception. 
Male subjects (even with a history of vasectomy) with partners of childbearing potential must 
use a male barrier method of contraception (ie, male condom with spermicide) in addition to a 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 54 of 69 
Internal Use Only Medical and Scientific Affairs 
second method of acceptable contraception by female partner from Check-in until 7 days after 
the EOS visit. Acceptable methods of contraception for female partners include: 
 hormonal injection  
 combined oral contraceptive pill or progestin/progestogen-only pill  
 combined hormonal patch  
 combined hormonal vaginal ring  
 surgical method (bilateral tubal ligation or regulatory approved method of hysteroscopic 
bilateral tubal occlusion)  
 hormonal implant  
 hormonal or non-hormonal intrauterine device  
 over-the-counter sponge with spermicide  
 cervical cap with spermicide  
 diaphragm with spermicide.  
Male subjects are required to refrain from donation of sperm from Check-in until 7 days after the 
EOS visit. 
Sexual Abstinence  
Subjects who practice true abstinence, because of the subject’s lifestyle choice (ie, the subject 
should not become abstinent just for the purpose of study participation), are exempt from 
contraceptive requirements. Periodic abstinence (eg, calendar, ovulation, symptothermal, 
postovulation methods) and withdrawal are not acceptable methods of contraception. 
For subjects who practice true abstinence, subjects must be abstinent for at least 6 months prior 
to Screening and must agree to remain abstinent from the time of signing the Informed Consent 
Form (ICF) until 7 days after the EOS visit.  
Same-sex Relationships 
For subjects who are exclusively in same-sex relationships, contraceptive requirements do not 
apply. 
If a subject who is in a same-sex relationship at the time of signing the ICF becomes engaged in 
a heterosexual relationship, they must agree to use contraception from the time of signing the 
ICF until 7 days after the EOS visit.   


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 55 of 69 
Internal Use Only Medical and Scientific Affairs 
Appendix 5: Collection of Pregnancy and Lactation Information 
Collection of Pregnancy Information 
Male Subjects with Partners Who Become Pregnant or Were Pregnant at the Time of Enrollment 
 In the event a male subject fathers a child during treatment, and for an additional 7 days 
after end of study (EOS), the information will be recorded on the Pregnancy Notification 
Form. The form (see Figure 3) must be submitted to Amgen Global Patient Safety within 
24 hours of the site’s awareness of the pregnancy. (Note: Sites are not required to provide 
any information on the Pregnancy Notification Form that violates the country or regions 
local privacy laws). 
 The Investigator will attempt to obtain a signed consent for release of pregnancy and 
infant health information directly from the pregnant female partner to obtain additional 
pregnancy information. 
 After obtaining the female partner’s signed consent for release of pregnancy and infant 
health information, the Investigator will collect pregnancy outcome and infant health 
information on the pregnant partner and her baby and complete the pregnancy 
questionnaires. This information will be forwarded to Amgen Global Patient Safety. 
 Generally, infant follow-up will be conducted up to 12 months after the birth of the child 
(if applicable).  
 Any termination of the pregnancy will be reported to Amgen Global Patient Safety 
regardless of fetal status (presence or absence of anomalies) or indication for procedure. 
Collection of Lactation Information 
 The Investigator will collect lactation information on any female subject who breastfeeds 
while taking protocol-required therapies through 7 days after EOS. 
 Information will be recorded on the Lactation Notification Form (Figure 4) and submitted 
to Amgen Global Patient Safety within 24 hours of the Investigator’s awareness of the 
event. 
 Study treatment will be discontinued if the female subject breastfeeds during the study. 
With the female subject’s signed consent for release of mother and infant health information, the 
Investigator will collect mother and infant health information and complete the lactation 
questionnaire on any female subject who breastfeeds while taking protocol-required therapies 
through 7 days after discontinuing protocol-required therapies.


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 56 of 69 
Internal Use Only Medical and Scientific Affairs 
Figure 3:  
Pregnancy Notification Form 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 57 of 69 
Internal Use Only Medical and Scientific Affairs 
Figure 4:  
Lactation Notification Form 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 58 of 69 
Internal Use Only Medical and Scientific Affairs 
Appendix 6: Regulatory, Ethical, and Study Oversight Considerations 
Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines. 
 Applicable International Conference on Harmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines. 
 Applicable laws and regulations. 
The protocol, protocol amendments, Informed Consent Form (ICF), Investigator’ Brochure, and 
other relevant documents (eg, advertisements) must be submitted to an Institutional Review 
Board (IRB) by the Investigator and reviewed and approved by the IRB before the study is 
initiated. 
Any amendments to the protocol will require IRB and regulatory authority (as locally required) 
approval before implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study subjects. 
The Investigator will be responsible for the following: 
 Providing written summaries of the status of the study to the IRB annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB. 
 Notifying the IRB of serious adverse events or other significant safety findings as 
required by IRB procedures. 
 Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local regulations. 
Finances and Insurance 
Financing and insurance will be addressed in a separate agreement. 
Informed Consent 
An initial sample ICF will be provided for the Investigator (or designee) to prepare the informed 
consent document to be used at his or her site. Updates to the sample ICF are to be 
communicated formally in writing from the Study Manager to the Investigator. The written ICF 
is to be prepared in the language(s) of the potential study participant population. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 59 of 69 
Internal Use Only Medical and Scientific Affairs 
The Investigator or his/her delegated representative will explain to the subject, or his/her legally 
authorized representative, the aims, methods, anticipated benefits, and potential hazards of the 
study before any protocol-specific screening procedures or any investigational product(s) is/are 
administered and answer all questions regarding the study. 
Subjects must be informed that their participation is voluntary. Subjects or their legally 
authorized representative (defined as an individual or other body authorized under applicable law 
to consent, on behalf of a prospective subject, to the subject’s participation in the clinical study) 
will then be required to sign a statement of informed consent that meets the requirements of 
21 CFR 50, local regulations, ICH guidelines, and the IRB or study site. 
The medical record must include a statement that written informed consent was obtained before 
the subject was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF. 
The acquisition of informed consent and the subject’s agreement or refusal of his/her notification 
of the primary care physician is to be documented in the subject’s medical records, and the ICF 
is to be signed and personally dated by the subject or a legally acceptable representative and by 
the person who conducted the informed consent discussion. Subject withdrawal of consent or 
discontinuation from study treatment and/or procedures must also be documented in the subject’s 
medical records. 
Subjects must be re-consented to the most current version of the ICF during their participation in 
the study. 
The original signed ICF is to be retained in accordance with institutional policy, and a copy of 
the ICF must be provided to the subject or the subject’s legally authorized representative. 
If a potential subject is illiterate or visually impaired and does not have a legally acceptable 
representative, the Investigator must provide an impartial witness to read the ICF to the subject 
and must allow for questions. Thereafter, both the subject and the witness must sign the ICF to 
attest that informed consent was freely given and understood. (Refer to ICH GCP guideline, 
Section 4.8.9.) 
A subject who is rescreened is not required to sign another ICF if the rescreening occurs within 
21 days from the previous ICF signature date and the same version of the ICF is in use at the 
time of rescreening. 
Subject Data Protection 
The Investigator must ensure that the subject’s confidentiality is maintained for documents 
submitted to the Sponsor. 
Subjects will be assigned a unique identifier by the Sponsor (or designee). Any subject records or 
datasets that are transferred to the Sponsor will contain the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred.  


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 60 of 69 
Internal Use Only Medical and Scientific Affairs 
On the electronic Case Report Form (eCRF) demographics page, in addition to the unique 
subject identification number (Section 4.4), include the age at time of enrollment. 
For serious adverse events reported to the Sponsor (or designee), subjects are to be identified by 
their unique subject identification number (Section 4.4), initials (for faxed reports, in accordance 
with local laws and regulations) and age (in accordance with local laws and regulations). 
Documents that are not submitted to the Sponsor (eg, signed ICFs) are to be kept in confidence 
by the Investigator, except as described below. 
In compliance with ICH GCP Guidelines, it is required that the Investigator and institution 
permit authorized representatives of the company, of the regulatory agency(s), and the IRB direct 
access to review the subject’s original medical records for verification of study-related 
procedures and data. Direct access includes examining, analyzing, verifying, and reproducing 
any records and reports that are important to the evaluation of the study. 
The Investigator is obligated to inform and obtain the consent of the subject to permit such 
individuals to have access to his/her study-related records, including personal information. 
Disclosure 
All information provided regarding the study, as well as all information collected and/or 
documented during the course of the study, will be regarded as confidential information of the 
Sponsor, Amgen Inc. The Investigator (or designee) agrees not to disclose such information in 
any way without prior written permission from the Sponsor. The information in this document 
cannot be used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written permission from the Sponsor. 
The Investigator must ensure that the subject’s confidentiality is maintained for documents 
submitted to Amgen. 
Subjects will be assigned a unique identifier by the Sponsor (or designee). Any subject records or 
datasets that are transferred to the Sponsor will contain the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred.  
On the eCRF demographics page, in addition to the unique subject identification number 
(Section 4.4), include the age at time of enrollment. 
For serious adverse events reported to Amgen, subjects are to be identified by their unique 
subject identification number (Section 4.4), initials (for faxed reports, in accordance with local 
laws and regulations), and age (in accordance with local laws and regulations). 
Documents that are not submitted to Amgen (eg, signed ICFs) are to be kept in confidence by the 
Investigator, except as described below. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 61 of 69 
Internal Use Only Medical and Scientific Affairs 
Data Quality Assurance 
The following data quality steps will be implemented: 
 All relevant subject data relating to the study will be recorded on eCRFs unless directly 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The 
Investigator is responsible for verifying that data entries are accurate and correct by 
electronically signing the eCRF. 
 The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF. 
 The Investigator must permit study-related monitoring, audits, IRB review, and 
regulatory agency inspections and provide direct access to source data documents. 
 The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data. Predefined agreed risks, monitoring thresholds, quality 
tolerance thresholds, controls, and mitigation plans will be documented in a risk 
management register. Additional details of quality checking to be performed on the data 
may be included in a Data Management Plan. 
 A Study Monitor will perform ongoing source data verification to confirm that data 
entered into the eCRF by authorized site personnel are accurate, complete, and verifiable 
from source documents; that the safety and rights of subjects are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements. 
 Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the Investigator in accordance with 21 CFR 312.62(c) unless local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the Sponsor. No 
records may be transferred to another location or party without written notification to the 
Sponsor. 
Investigator Documentation Responsibilities 
All individual, subject-specific study data will also be entered into a 21 CFR Part 11-compliant 
electronic data capture (EDC) system on an eCRF in a timely fashion. 
All data generated from external sources (eg, laboratory and bioanalytical data), and transmitted 
to the Sponsor or designee electronically, will be integrated with the subject’s eCRF data in 
accordance with the Data Management Plan. 
An eCRF must be completed for each enrolled subject who undergoes any screening procedures, 
according to the eCRF completion instructions. The Sponsor or Contract Research Organization 
will review the supporting source documentation against the data entered into the eCRFs to 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 62 of 69 
Internal Use Only Medical and Scientific Affairs 
verify the accuracy of the electronic data. The Investigator will ensure that corrections are made 
to the eCRFs and that data queries are resolved in a timely fashion by the study staff. 
The Investigator will sign and date the eCRF via the EDC system’s electronic signature 
procedure. These signatures will indicate that the Investigator reviewed and approved the data on 
the eCRF, data queries, and site notifications. 
Publications 
The policy for publication of data obtained during this study will be documented in the Clinical 
Study Agreement. 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 63 of 69 
Internal Use Only Medical and Scientific Affairs 
Appendix 7: Hepatotoxicity Stopping Rules: Suggested Actions and Follow-up Assessments 
Subjects with abnormal hepatic laboratory values (ie, alkaline phosphatase [ALP], aspartate 
aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin [TBL]) and/or 
international normalized ratio (INR) and/or signs/symptoms of hepatitis (as described below) 
may meet the criteria for withholding or permanent discontinuation of Amgen investigational 
product or other protocol-required therapies, as specified in the Guidance for Industry 
Drug-Induced Liver Injury: Premarketing Clinical Evaluation, July 2009. 
Criteria for Withholding and/or Permanent Discontinuation of Amgen Investigational 
Product and Other Protocol-required Therapies Due to Potential Hepatotoxicity 
The following stopping and/or withholding rules apply to subjects for whom another cause of 
their changes in liver biomarkers (TBL, INR, and transaminases) has not been identified. 
Important alternative causes for elevated AST/ALT and/or TBL values include, but are not 
limited to: 
 Hepatobiliary tract disease 
 Viral hepatitis (eg, hepatitis A/B/C/D/E, Epstein-Barr Virus, cytomegalovirus, herpes 
simplex virus, varicella, toxoplasmosis, and parvovirus) 
 Right-sided heart failure, hypotension, or any cause of hypoxia to the liver causing 
ischemia 
 Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary 
supplements, plants, and mushrooms 
 Heritable disorders causing impaired glucuronidation (eg, Gilbert’s syndrome, 
Crigler-Najjar syndrome) and drugs that inhibit bilirubin glucuronidation (eg, indinavir, 
atazanavir) 
 Alpha-one antitrypsin deficiency 
 Alcoholic hepatitis 
 Autoimmune hepatitis 
 Wilson’s disease and hemochromatosis 
 Nonalcoholic fatty liver disease including steatohepatitis 
 Non-hepatic causes (eg, rhabdomylosis, hemolysis). 
If investigational product(s) is/are withheld, the subject is to be followed for possible 
drug-induced liver injury (DILI) according to recommendations in the last section of this 
appendix. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 64 of 69 
Internal Use Only Medical and Scientific Affairs 
Rechallenge may be considered if an alternative cause for impaired liver tests (ALT, AST, ALP) 
and/or elevated TBL is discovered and the laboratory abnormalities resolve to normal or baseline 
(see next section in this appendix). 
Table 2: 
Conditions for Withholding and/or Permanent Discontinuation of Amgen 
Investigational Product and Other Protocol-required Therapies Due to 
Potential Hepatotoxicity 
Analyte 
Temporary Withholding 
Permanent Discontinuation 
TBL 
3x ULN at any time 
2x ULN 
INR 
-- 
OR 
1.5x ULN (for subjects 
not on anticoagulation 
therapy) 
AND 
AST/ALT 
8x ULN at any time 
5x ULN but 8x ULN for 2 weeks 
5x ULN but 8x ULN and unable to 
adhere to enhanced monitoring schedule 
3x ULN with clinical signs or symptoms 
that are consistent with hepatitis (such as 
right upper quadrant pain/tenderness, fever, 
nausea, vomiting, and jaundice) 
OR 
In the presence of no 
important alternative 
causes for elevated 
AST/ALT and/or TBL 
values 
3x ULN (when baseline 
was  ULN) 
ALP 
8x ULN at any time 
-- 
Abbreviations: ALP  alkaline phosphatase; ALT  alanine aminotransferase; AST  aspartate aminotransferase; 
INR  international normalized ratio; TBL  total bilirubin; ULN  upper limit of normal. 
 
Criteria for Rechallenge of Amgen Investigational Product and Other Protocol-required 
Therapies After Potential Hepatotoxicity 
The decision to rechallenge the subject is to be discussed and agreed upon unanimously by the 
subject, Investigator, and Amgen. 
If signs or symptoms recur with rechallenge, then sotorasib is to be permanently discontinued. 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 65 of 69 
Internal Use Only Medical and Scientific Affairs 
Subjects who clearly meet the criteria for permanent discontinuation (as described in Table 2) are 
never to be rechallenged. 
Drug-induced Liver Injury Reporting and Additional Assessments 
Reporting 
To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or ALT and 
TBL and/or INR elevation, according to the criteria specified above, require the following: 
 The event is to be reported to Amgen as a serious adverse event within 24 hours of 
discovery or notification of the event (i.e., before additional etiologic investigations have 
been concluded). 
 The appropriate electronic Case Report Form (eCRF) that captures information necessary 
to facilitate the evaluation of treatment-emergent liver abnormalities is to be completed 
and sent to Amgen. 
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse events if 
they meet the criteria for a serious adverse event defined in Appendix 1. 
Additional Clinical Assessments and Observation 
All subjects in whom investigational product(s) or protocol-required therapies is/are withheld 
(either permanently or conditionally) due to potential DILI as specified in Table 2 or who 
experience AST or ALT elevations 3 x upper limit of normal (ULN) or 2-fold increases above 
baseline values for subjects with elevated values before drug are to undergo a period of “close 
observation” until abnormalities return to normal or to the subject’s baseline levels. 
Assessments that are to be performed during this period include: 
 Repeat AST, ALT, ALP, bilirubin (total and direct), and INR within 24 hours 
 In cases of TBL 2x ULN or INR  1.5, retesting of liver tests, bilirubin (total and direct) 
and INR is to be performed every 24 hours until laboratory abnormalities improve. 
Testing frequency of the above laboratory tests may decrease if the abnormalities stabilize or the 
investigational product(s) or protocol-required therapies has/have been discontinued AND the 
subject is asymptomatic. 
Initiate investigation of alternative causes for elevated AST or ALT and/or elevated TBL. 
The following are to be considered depending on the clinical situation: 
 Complete blood count with differential to assess for eosinophilia 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 66 of 69 
Internal Use Only Medical and Scientific Affairs 
 Serum total immunoglobulin G, anti-nuclear antibody anti-smooth muscle antibody, and 
liver kidney microsomal antibody-1 to assess for autoimmune hepatitis 
 Serum acetaminophen (paracetamol) levels 
 A more detailed history of: 
o Prior and/or concurrent disease or illness 
o Exposure to environmental and/or industrial chemical agents 
o Symptoms (if applicable) including right upper quadrant pain, hypersensitivity-
type reactions, fatigue, nausea, vomiting, and fever 
o Prior and/or concurrent use of alcohol, recreational drugs, and special diets 
o Concomitant use of medications (including nonprescription medicines and herbal 
and dietary supplements), plants, and mushrooms 
 Viral serologies 
 Creatine phosphokinase, haptoglobin, lactate dehydrogenase, and peripheral blood smear 
 Appropriate liver imaging if clinically indicated 
 Appropriate blood sampling for pharmacokinetic analysis, if this has not already been 
collected 
 Hepatology consult (liver biopsy may be considered in consultation with a hepatologist). 
Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal or are considered stable by the Investigator. The 
“close observation period” is to continue for a minimum of 4 weeks after discontinuation of all 
investigational product(s) and protocol-required therapies. 
The potential DILI event and additional information such as medical history, concomitant 
medications, and laboratory results must be captured in the corresponding eCRFs. 
 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
AMG 510 20220024 
18 May 2022 
Page 67 of 69 
Internal Use Only Medical and Scientific Affairs 
Appendix 8: Schedule of Assessments


Protocol 
CONFIDENTIAL 
Labcorp Drug Development: 8493285 
AMG 510 20220024 
18 May 2022 
Page 68 of 69 
Internal Use Only Medical and Scientific Affairs 
 
   Study Procedures 
Screening 
Check-
in 
Sotorasib (Day 1) and Omeprazole (Day 4-8) 
Alone 
Sotorasib in Combination with 
Omeprazole and acidic beverage 
Days -28  
to -2 
Day -1 
Day 1 
Day 2 
Day 3  
Days 4 to 7 
Day 8 
Day 9 
Day 10 
Day 11 
(EOS/ET) 
Confined to the CRU 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
Outpatient Visit 
X 
  
  
  
  
  
 
  
  
  
Inclusion/Exclusion Criteria 
X 
X 
  
  
  
  
 
  
  
  
Informed Consent 
X 
  
  
  
  
  
 
  
  
  
Demographics 
X 
  
  
  
  
  
 
  
  
  
Serology 
X 
  
  
  
  
 
 
  
  
  
Medical History 
X 
Xa 
  
  
  
 
 
  
  
  
Height and BMI 
X 
  
  
  
  
 
 
  
  
  
Weight 
X 
X 
  
  
  
  
 
  
  
 Xb 
Drug Screen 
X 
X 
  
  
  
  
 
  
  
  
Alcohol Test 
 
X 
  
  
  
  
 
  
  
  
Pregnancy Test (females only)c 
X 
X 
  
  
  
  
 
  
  
 Xb 
FSH (postmenopausal females 
only) 
X 
  
  
  
  
 
 
  
  
  
12-lead Electrocardiogramd 
X 
X 
X 
 
  
  
 
X 
  
Xb 
Vital Signse 
X 
X 
X 
X 
 X 
 
 
X 
X  
Xb 
Clinical Laboratory Evaluationsf 
X 
X 
  
  
  
 
X 
  
  
 Xb 
eGFRg 
X 
X 
  
  
  
  
 
  
  
  
Thyroid-stimulating Hormone 
X 
X 
 
 
 
 
 
 
 
X 
Physical Examinationh 
 X 
X 
  
  
  
  
 
  
  
 Xb 
Sotorasib Dosei 
  
  
X 
  
  
 
 
X 
  
 
Omeprazole Dosej  
  
  
  
 
 
X 
X 
X 
  
  
Sotorasib PK Blood Samplesk 
  
  
X 
X 
X  
 
 
X 
X 
X 
Adverse Event Monitoringl 
 
 
X 
Serious Adverse Event 
Monitoringl 
X 
X 
Prior/Concomitant Medicationsm 
X 
X 


Protocol 
CONFIDENTIAL 
Labcorp Drug Development: 8493285 
AMG 510 20220024 
18 May 2022 
Page 69 of 69 
Internal Use Only Medical and Scientific Affairs 
Abbreviations: BMI  body mass index; CRU  Clinical Research Unit; eGFR  estimated glomerular filtration rate; EOS  end of study; AT  early termination; 
FSH  follicle-stimulating hormone; PK  pharmacokinetic. 
a Interim medical history only. 
b Assessment to be performed at the EOS or ET. 
c Performed in serum at Screening and in urine at all other times. A positive urine pregnancy test will be confirmed with a serum pregnancy test. 
d Electrocardiograms (ECGs) will be collected after the subject has rested in the supine position for at least 5 minutes, and will be obtained prior to the scheduled blood 
draws. ECGs will be assessed at Screening, Check-in, at predose on Days 1 and 9, and at 0.5, 2, and 4 hours following sotorasib administration; and at EOS or ET. 
Triplicate ECGs will only be collected at Screening and Check-in if needed to verify eligibility criteria. The 30-minute postdose ECG measurement will have a 
collection window of  5 minutes, the 2-hour postdose ECG measurement will have a collection window of  5 minutes, and the 4-hour postdose ECG measurement 
will have a collection window of  10 minutes. 
e Vital signs measurements (oral body temperature, respiratory rate, supine blood pressure, and supine heart rate) will be carried out, prior to having blood drawn, at 
Screening, Check-in, predose, and at 1, 24, and 48 hours after each dose of sotorasib, and at EOS or ET. Blood pressure and heart rate will be measured using the same 
arm for each reading after the subject has been resting in the supine position for at least 5 minutes. 
f Clinical chemistry (fasted at least 8 hours), hematology, and urinalysis. 
g eGFR will be calculated using the Modification of Diet in Renal Disease equation. 
h A full physical examination at Screening and Check-in and a symptom-directed physical examination at EOS or ET. 
i Dose administration of sotorasib is to occur during the mornings of Days 1 and 9 following an overnight fast of at least 10 hours. On Day 9, sotorasib administration 
will occur within 5 minutes after administration of omeprazole with an acidic beverage (Coca-Cola). 
j Dose administration of omeprazole is to occur during the mornings of Days 4 through 9 following an overnight fast of at least 10 hours. 
k Blood samples for determination of sotorasib plasma concentrations and PK parameters will be collected: Predose (Hour 0), 0.5 , 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 
48 hours postdose following administration of sotorasib on Days 1 and 9. The PK sample collected 30 minutes postdose will have a sampling window of  2 minutes, 
samples collected from 1 through 3 hours postdose will have a sampling window of  5 minutes, samples collected from 4 through 10 hours postdose will have a 
sampling window of  10 minutes, and samples collected from 12 through 48 hours postdose will have a sampling window of  20 minutes. Times of all PK samples 
will be recorded to the nearest minute. 
l Adverse events will be recorded from initiation of study treatment on Day 1 until EOS or ET. Serious adverse events will be recorded from the time the subject signs the 
Informed Consent Form through 30 days after the last dose of study treatment or until EOS or ET (whichever is later). 
m Prior and concomitant medication administration will be recorded from the time the subject signs the Informed Consent Form. In addition, all Investigator-approved 
medications (prescription or over the counter), all herbal medicines (eg, St. John’s wort), vitamins, and supplements taken by a subject within 30 days or 5 half-lives 
(whichever is longer) prior to enrollment will be recorded on the subject’s electronic Case Report Form. 
 

SAP_001.pdf: 
TITLE PAGE 
Statistical Analysis Plan 
An Open label Study to Evaluate the Impact of Omeprazole, A Proton 
Pump Inhibitor, on the Pharmacokinetics of Sotorasib Coadministered 
with an Acidic Beverage in Healthy Volunteers 
SAP Status: Final 
SAP Version: 1.0 
SAP Date: 14 September 2022 
Investigational Medicinal Product: Sotorasib (AMG 510) 
Protocol Reference: 20220024 
Labcorp Drug Development Study: 8493285 
Sponsor: 
Amgen Inc. 
One Amgen Center Drive 
Thousand Oaks, California 91320 
Study Site: 
Labcorp Clinical Research Unit Inc. 
1341 W. Mockingbird Ln., Suite 200E 
Dallas, TX 75247 
Information described herein is confidential and may be disclosed only with the express 
written permission of the sponsor. 
Page 2 of 24
NCT Number: NCT05497557
This NCT number has been applied to the document for
purposes of posting on Clinicaltrials.gov


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 2 of 21 
ST-AD-031 Version 02 
TABLE OF CONTENTS 
TITLE PAGE ............................................................................................................................. 1 
TABLE OF CONTENTS ........................................................................................................... 2 
LIST OF IN-TEXT TABLES AND FIGURES ......................................................................... 3 
LIST OF ABBREVIATIONS .................................................................................................... 4 
1. INTRODUCTION ................................................................................................................. 6 
2. STUDY OBJECTIVES .......................................................................................................... 6 
3. STUDY ENDPOINTS ........................................................................................................... 7 
3.1. Primary Endpoints: ......................................................................................................... 7 
3.2. Secondary Endpoints: ..................................................................................................... 7 
4. STUDY DESIGN................................................................................................................... 7 
5. SAMPLE SIZE JUSTIFICATION ........................................................................................ 8 
6. STUDY TREATMENTS ....................................................................................................... 8 
7. DEFINITIONS OF POPULATIONS .................................................................................... 9 
7.1. All Subjects Population ................................................................................................... 9 
7.2. Safety Population ............................................................................................................ 9 
7.3. Pharmacokinetic Population ........................................................................................... 9 
8. STATISTICAL METHODOLOGY ...................................................................................... 9 
8.1. General ............................................................................................................................ 9 
8.1.1. Handling of Data Quality Issues Due to Coronavirus Disease 2019 and Related 
Restrictions ....................................................................................................................... 10 
8.1.2. Calculation of the Summary Statistics ................................................................... 11 
8.1.3. Repeat and Unscheduled Readings ........................................................................ 11 
8.1.4. Definitions of Baseline, Change from Baseline, and Percentage Change from 
Baseline ............................................................................................................................ 12 
8.2. Subject Disposition and Population Assignment .......................................................... 12 
8.3. Screening Demographics .............................................................................................. 12 
8.4. Prior and Concomitant Medication ............................................................................... 12 
8.5. Pharmacokinetic Assessments ...................................................................................... 13 
8.5.1. Pharmacokinetic Analysis ...................................................................................... 13 
8.5.2. Presentation of Pharmacokinetic Data ................................................................... 15 
8.5.3. Pharmacokinetic Statistical Methodology .............................................................. 16 
8.6. Safety and Tolerability Assessments ............................................................................ 16 
Page 3 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 3 of 21 
ST-AD-031 Version 02 
8.6.1. Adverse Events ....................................................................................................... 16 
8.6.2. Clinical Laboratory Parameters .............................................................................. 18 
8.6.3. Vital Signs Parameters ........................................................................................... 18 
8.6.4. 12-lead Electrocardiogram Parameters .................................................................. 18 
8.6.5. Other Assessments ................................................................................................. 19 
8.6.6. Safety and Tolerability Statistical Methodology .................................................... 19 
9. INTERIM ANALYSES ....................................................................................................... 19 
10. SIGNIFICANT CHANGES FROM THE PROTOCOL-SPECIFIED ANALYSES ........ 19 
11. REFERENCES .................................................................................................................. 19 
12. APPENDICES ................................................................................................................... 21 
Appendix 1: 
Document History ................................................................................ 21 
LIST OF IN-TEXT TABLES AND FIGURES 
Table 1: 
Presentation of Study Treatments in TFLs ............................................................. 9 
Figure 1: 
Study Schematic ...................................................................................................... 8 
Page 4 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 4 of 21 
 
 
ST-AD-031 Version 02 
 
LIST OF ABBREVIATIONS 
Abbreviations pertain to the statistical analysis plan (SAP) only (not the tables, figures, and 
listings [TFLs]). 
ADaM 
Analysis Data Model 
AE 
adverse event 
ANOVA 
analysis of variance 
AUCinf 
area under the plasma concentration-time curve from time zero extrapolated to 
infinity 
AUC0-tlast 
area under the plasma concentration-time curve from time zero to time of last 
quantifiable concentration 
BLQ 
below the limit of quantification 
CDISC 
Clinical Data Interchange Standards Consortium 
CI 
confidence interval 
CL/F 
apparent total clearance  
Cmax 
maximum observed plasma concentration 
COVID-19 
coronavirus disease 2019 
CSR 
clinical study report 
CTCAE 
Common Terminology Criteria for Adverse Events 
CV 
coefficient of variation 
DMP 
data management plan 
ECG 
electrocardiogram 
eCRF 
electronic case report form 
GLSM 
geometric least squares mean 
ICH 
International Council for/Conference on Harmonisation 
LLOQ 
lower limit of quantification 
ln 
natural log 
LSM 
least squares mean 
MedDRA 
Medical Dictionary for Regulatory Activities 
PK 
pharmacokinetic(s) 
QTcF 
QT interval corrected for heart rate using Fridericia’s formula 
SAP 
statistical analysis plan 
SD 
standard deviation 
SDV 
source document verification 
t1/2 
apparent plasma terminal elimination half-life 
TEAE 
treatment-emergent adverse event 
TFL 
table, figure, and listing 
tlag 
absorption lag time  
tmax 
time of the maximum observed plasma concentration 
Vz/F 
apparent volume of distribution during the terminal phase  
WHODrug 
World Health Organization Drug Dictionary  
Page 5 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 5 of 21 
 
 
ST-AD-031 Version 02 
 
λz 
apparent terminal elimination rate constant 
  
Page 6 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 6 of 21 
ST-AD-031 Version 02 
1. INTRODUCTION
This SAP has been developed after review of the clinical study protocol (Final Protocol dated 
18 May 2022) and electronic case report form (eCRF).  
This SAP describes the planned analysis of the pharmacokinetic (PK), safety, and tolerability 
data from this study. A detailed description of the planned TFLs to be presented in the 
clinical study report (CSR) is provided in the accompanying TFL shells document.  
In general, the analyses are based on information from the protocol, unless they have been 
modified by agreement with Amgen Inc. A limited amount of information about this study 
(eg, objectives, study design) is given to help the reader’s interpretation.  
This SAP must be finalized prior to the first subject enrollment (the point of enrollment 
occurs at the time of subject number allocation). Additionally, the SAP and TFL shells should 
be finalized prior to any programming activities commencing. 
This SAP supersedes any statistical considerations identified in the protocol; where 
considerations are substantially different, they will be so identified. If additional analyses are 
required to supplement the planned analyses described in this SAP, they may be performed 
and will be identified accordingly in the CSR. Any substantial deviations from this SAP will 
be agreed with Amgen Inc. and identified in the CSR.  
This SAP is written with consideration of the recommendations outlined in the International 
Conference on Harmonisation (ICH) E3 guideline Structure and Content of Clinical Study 
Reports, ICH E8 guideline General Considerations for Clinical Trials, ICH E9 guideline 
Statistical Principles for Clinical Trials, and ICH E9 R1 guideline Addendum on Estimands 
and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for 
Clinical Trials.1,2,3,4 
The document history is presented in Appendix 1. 
2. STUDY OBJECTIVES
The primary objective of the study is: 

to evaluate the effects of omeprazole (a PPI) and an acidic beverage on sotorasib PK
when administered orally in healthy volunteers.
The secondary objective of the study is: 

to evaluate safety and tolerability of sotorasib when coadministered with omeprazole
and an acidic beverage in healthy subjects.
Page 7 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 7 of 21 
 
 
ST-AD-031 Version 02 
 
3. STUDY ENDPOINTS  
3.1. Primary Endpoints: 
The primary endpoints of the study are sotorasib PK parameters on Days 1 and 9: 
 Cmax 
 AUCinf 
 area under the plasma concentration-time curve from time zero to time of last 
quantifiable concentration (AUClast) 
 
3.2. Secondary Endpoints: 
The secondary endpoints of the study are: 
 adverse events 
 clinical laboratory tests 
 12-lead ECGs 
 vital signs. 
4. STUDY DESIGN  
This will be a Phase 1, single-center (United States), open-label, fixed sequence study to 
investigate the effect of coadministration of omeprazole with an acidic beverage on the PK of 
sotorasib in healthy male and healthy female subjects. Up to 14 subjects will be enrolled to 
ensure that 12 subjects complete the study.  All subjects will receive each of the following 
treatments: 
 Day 1: 960 mg sotorasib (8 x 120 mg tablets) administered orally with 240 mL of 
water after an overnight fast of at least 10 hours 
 Days 4 to 8: 40 mg omeprazole (delayed release capsule) administered orally with 
240 mL of water QD after an overnight fast of at least 10 hours 
 Day 9: 40 mg omeprazole (delayed release capsule) followed by 960 mg sotorasib 
(8 x 120 mg tablets) administered orally within 5 minutes with 240 mL of an acidic 
beverage after an overnight fast of at least 10 hours. 
 
 
 
 
Page 8 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 8 of 21 
 
 
ST-AD-031 Version 02 
 
An overview of the study design is shown in Figure 1. 
Figure 1: 
Study Schematic 
 
Potential subjects will be screened to assess their eligibility to enter the study within 28 days 
prior to the first dose administration. Subjects will be admitted into the Clinical Research 
Unit (CRU) on Day -1 and be confined to the CRU until discharge/end of study (EOS) on 
Day 11. 
The total duration of study participation for each subject (from Screening through EOS visit) 
is anticipated to be approximately 5.5 weeks. 
The start of the study is defined as the date the first enrolled subject signs an Informed 
Consent Form (ICF). The point of enrollment occurs at the time of subject number allocation. 
The end of the study is defined as the date of the last subject’s last assessment (scheduled or 
unscheduled). 
5. SAMPLE SIZE JUSTIFICATION  
Approximately 14 subjects will be enrolled in order that approximately 12 subjects complete 
the study. The sample size for this study was based upon precedent set by other PK studies of 
a similar nature and was not based on power calculations.   
6. STUDY TREATMENTS  
The study treatment names, abbreviations, and ordering to be used in the TFLs are presented 
in Table 1.  
 
Page 9 of 24
Study Day 
-28 to -2 
-1 
( 
) 
Screening 
960 mg Sotorasib + 
water 
1 
4 
40 mg Omeprazole+ 
water 
8 
40 mg Omeprazole + 
960 mg Sotorasib + 
Coca-Cola® 
9 
Resident in the Clinical Research Unit 
End of Study 
II 


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 9 of 21 
 
 
ST-AD-031 Version 02 
 
Table 1: 
Presentation of Study Treatments in TFLs  
Study Treatment 
Order in TFLs 
Sotorasib administered alone  
1 
Omeprazole coadministered with Sotorasib and an acidic 
beverage 
2 
All TFLs will be based on actual treatments (eg, if subject was assigned to receive placebo 
but was wrongfully dosed with active treatment they would be summarized and listed under 
active treatment). 
7. DEFINITIONS OF POPULATIONS  
Any protocol deviations, including those due to coronavirus disease 2019 (COVID-19) and 
related restrictions (see Section 8.1.1), will be considered prior to database lock for their 
importance and taken into consideration when assigning subjects to populations. 
7.1. All Subjects Population  
The all subjects population will include all subjects who signed the ICF and had any study 
assessment recorded in the database per the protocol. 
7.2. Safety Population  
The safety population will include all subjects who received at least 1 dose of sotorasib and 
have at least 1 postdose safety assessment. 
7.3. Pharmacokinetic Population  
The PK population will include all subjects who received at least 1 dose of sotorasib and have 
evaluable PK data. The PK population for the primary endpoint analysis will include all 
subjects who received both sotorasib, and sotorasib in combination with omeprazole and an 
acidic beverage, and have evaluable PK data. A subject will be excluded from the PK 
summary statistics and statistical analysis if the subject has an adverse event of vomiting that 
occurs at or before 2 times median tmax or diarrhea within 24 hours of dosing.  
8. STATISTICAL METHODOLOGY  
8.1. General  
Listings will be provided for all data captured in the database, with the exception of medical 
history. Listings will include all subjects assigned to the all subjects population and include 
data up to the point of study completion or discontinuation. Subjects are generally considered 
to have completed the study if they complete the scheduled follow-up visit (rather than early 
termination visit). Any subject who discontinues the study will be identified accordingly in 
the listings. Summaries and statistical analyses will include the subjects assigned to the 
relevant population based on data type. 
Page 10 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 10 of 21 
 
 
ST-AD-031 Version 02 
 
Data analysis will be performed using the SAS® statistical software package Version 9.4 (or 
higher if a new version is issued during the study).  
Analysis Data Model (ADaM) datasets will be prepared using Clinical Data Interchange 
Standards Consortium (CDISC) ADaM Version 2.1 (or higher if a new version is issued 
during the study) and CDISC ADaM Implementation Guide Version 1.1 (or higher if a new 
version is issued during the study). Pinnacle 21 Community Validator Version 4.0.1 (or 
higher if a new version is issued during the study) will be utilized to ensure compliance with 
CDISC standards.  
For all statistical analyses, the hypothesis testing will be two one-sided t-test with each side 
tested on 0.05 significance level, unless specifically stated otherwise.  
Where reference is made to ‘valid’ data, this refers to non-missing data which meet the 
predetermined criteria (eg, are not flagged for exclusion).  
Where reference is made to ‘all calculations’, this includes, but is not limited to, summary 
statistics, statistical analyses, baseline derivation, changes from baseline and percentage 
changes from baseline. 
All figures will be produced on linear-linear or discrete-linear scales, as applicable, unless 
specifically stated otherwise. 
8.1.1. Handling of Data Quality Issues Due to Coronavirus Disease 2019 and Related 
Restrictions 
Due to COVID-19 and related restrictions, there is a high risk for impact to data integrity, 
with the recognized potential for: 
● Missed visits, caused by, for example: 
o Subject unable to travel to site due to restrictions, the need to quarantine, or 
COVID-19 infection 
o Subject unwilling to go to site due to fear of COVID-19 infection 
o Site postponing subject’s visit due to investigator not being available (eg, if they 
have been dispatched to hospital handling COVID19 infections) 
● Site unable to replenish supply of investigational product 
● Incomplete data entry by sites due to limited resources to support study or no access to 
source documents or to eCRF 
● Outstanding source document verification (SDV) due to sponsor or country restrictions 
on remote SDV, or no or limited access to site(s) for on-site visits 
● Unanswered queries 
Page 11 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 11 of 21 
 
 
ST-AD-031 Version 02 
 
At the time of the reporting of the study results, all protocol deviations due to COVID-19 or 
related restriction will be assessed for their severity and impact on the analyses. If needed, 
appropriate statistical methods will be applied as a mitigating action (eg, data might be 
categorized into 2 analysis groups, with and without COVID-19 and related restrictions 
impact); however, this will exclude any imputations of the missing values. Any mitigating 
actions will be agreed with Amgen Inc in advance and identified in the CSR.  
8.1.2. Calculation of the Summary Statistics  
For continuous data the following rules will be applied:  
● Missing values will not be imputed, unless specifically stated otherwise.  
● Unrounded data will be used in the calculation of summary statistics.  
● If the number of subjects with valid observations (n) <3, summary statistics will not be 
calculated, with the exception of n, minimum, and maximum.  
● In general, as early termination data are not associated with any scheduled timepoint, 
they will be excluded from all calculations of summary statistics and statistical 
analyses. Exceptions may be made where justified. 
For categorical data the following rules will be applied:  
● For ordered categorical data (eg, adverse event [AE] severity), all categories between 
the possible minimum and maximum categories will be included, even if n = 0 for a 
given category.  
● For non-ordered categorical data (eg, race), only those categories for which there is at 
least 1 subject represented will be included; unless specifically stated otherwise.  
● Missing values will not be imputed, unless specifically stated otherwise. A ‘missing’ 
category will be included for any parameter for which information is missing. This will 
ensure that the population size totals are consistent across different parameters.  
8.1.3. Repeat and Unscheduled Readings  
For vital signs and 12-lead ECG data only, any predose value recorded in addition to the 
original value or a postdose value recorded within 15 minutes of the original value will be 
defined as a repeat value; any postdose value recorded more than 15 minutes after the 
original value will be defined as an unscheduled value. For all other data types (eg, laboratory 
parameters), any value recorded in addition to the original value will be defined as an 
unscheduled value.  
The original value will be replaced by the last associated repeat value in all calculations. 
Page 12 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 12 of 21 
 
 
ST-AD-031 Version 02 
 
As unscheduled values are not associated with any scheduled timepoint, they will be 
excluded from all calculations, with the exception of the baseline derivation (see 
Section 8.1.4) and 12-lead ECG outlier analysis (see Section 8.6.4).  
8.1.4. Definitions of Baseline, Change from Baseline, and Percentage Change from 
Baseline  
The baseline will be defined as the last value recorded prior to dosing. If the date/time of the 
value is incomplete or missing, it will be excluded from the baseline calculation, unless the 
incomplete date/time indicates the value was recorded prior to dosing.  
Individual changes from baseline will be calculated by subtracting the individual subject’s 
baseline value from the value at the postdose timepoint.  
Individual percentage changes from baseline will be calculated by subtracting the individual 
subject’s baseline value from the value at the postdose timepoint, then dividing this 
calculated value by the individual subject’s baseline value and multiplying by 100.   
The summary statistics for change from baseline and percentage changes from baseline will 
be derived from individual subjects’ values (eg, mean change from baseline will be the mean 
of the individual changes from baseline for all subjects, rather than difference between the 
mean value at the postdose timepoint and mean value at baseline).   
See Section 8.1.3 for more detail on handling repeat and unscheduled readings in the 
calculations.  
8.2. Subject Disposition and Population Assignment  
Subject disposition and population assignment will be listed.  
A summary table by treatment will be provided, based on the safety population.   
8.3. Screening Demographics 
The screening demographics including age, sex, race, ethnicity, height, body weight, and 
body mass index will be listed.  
A summary table by treatment will be provided, based on the safety population.  
8.4. Prior and Concomitant Medication  
Prior medication will be defined as medication that ends prior to the first dose. Concomitant 
medication will be defined as medication that starts during or after the first dose or starts but 
does not end prior to the first dose. 
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHODrug) Global, Format B3, Version March 2022 (or later if a new version is 
Page 13 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 13 of 21 
 
 
ST-AD-031 Version 02 
 
issued during the study; see the data management plan [DMP] for more details). Prior and 
concomitant medications will be listed. 
8.5. Pharmacokinetic Assessments  
8.5.1. Pharmacokinetic Analysis 
The following PK parameters will be determined where possible from the plasma 
concentrations of sotorasib using noncompartmental methods in validated software program 
Phoenix WinNonlin (Certara, Version 8.1.1 or higher): 
Parameter 
Unitsa 
Definition 
AUC0-tlast 
h*ng/mL 
area under the concentration-time curve from time 0 to the time 
of the last quantifiable concentration (tlast)b 
AUCinf 
h*ng/mL 
area under the concentration-time curve from time 0 extrapolated 
to infinityc 
Cmax 
ng/mL 
maximum observed concentration 
tmax 
h 
time of the maximum observed concentration 
tlast 
h 
time of the last quantifiable concentration 
t1/2 
h 
apparent terminal elimination half-life 
CL/F 
L/h 
apparent total clearance 
Vz/F 
L 
apparent volume of distribution during the terminal phase 
a Units are based on concentration units (provided by the bioanalytical lab or preferred units for presentation of PK 
parameters) and dose units used in the study. 
b The AUC will be calculated using the linear trapezoidal (linear interpolation) rule. 
c Based on the last observed quantifiable concentration 
Additional PK parameters may be determined where appropriate. 
Pharmacokinetic analysis will be carried out where possible using actual blood sampling 
times postdose. If an actual time is missing, the sample concentration result will be treated as 
missing unless there is scientific justification to include the result using the nominal time.  
The parameters Cmax, tlast, and tmax will be obtained directly from the concentration-time 
profiles. If Cmax occurs at more than 1 timepoint, tmax will be assigned to the first occurrence 
of Cmax. 
8.5.1.1. Criteria for the Calculation of Apparent Terminal Elimination Rate Constant 
and Half-life 
The start of the terminal elimination phase for each subject will be defined by visual 
inspection and generally will be the first point at which there is no systematic deviation from 
the log-linear decline in concentrations. 
The apparent terminal elimination rate constant (λz) will only be calculated when a reliable 
estimate can be obtained using at least 3 data points, preferably not including Cmax, and the 
adjusted coefficient for determination of exponential fit (R2-adj) of the regression line is ≥0.8. 
Page 14 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 14 of 21 
 
 
ST-AD-031 Version 02 
 
Parameters requiring λz for their calculation (eg, AUC0-∞, t1/2, CL/F, Vz/F) will only be 
calculated if the R2-adj value of the regression line is ≥0.8. 
The following regression-related diagnostic PK parameters will be determined, when 
possible: 
Parameter 
Units 
Definition 
%AUCextrap 
% 
percentage of AUC due to extrapolation from the last quantifiable 
concentration to infinity 
λz 
1/h 
apparent terminal elimination rate constant 
λz Upper 
h 
end of exponential fit 
λz Lower 
h 
start of exponential fit 
λz N 
NA 
number of data points included in the log-linear regression 
λz Span Ratio 
NA 
time period over which λz was determined as a ratio of t1/2 
R2-adj 
NA 
adjusted coefficient for determination of exponential fit 
Where possible, the span of time used in the determination of λz (ie, the difference between λz 
Upper and λz Lower) should be ≥2 half-lives. If the λz Span Ratio is <2, the robustness of the 
t1/2 values will be discussed in the clinical study report (CSR). 
8.5.1.2. Criteria for Calculation and Reporting of Area Under the Concentration-time 
Curve 
The minimum requirement for the calculation of area under the concentration-time curve 
(AUC) will be the inclusion of at least 3 consecutive concentrations above the lower limit of 
quantification. If there are only 3 consecutive concentrations, at least 1 should follow Cmax. 
An exception may be made for metabolites, where Cmax may be the last timepoint.  
If the extrapolated area is >20%, AUCinf (and derived parameters) will be listed but flagged 
and excluded from statistics. 
If AUCinf cannot be determined reliably for all subjects, an alternative AUC measure, such as 
AUC to a fixed timepoint or AUC0-tlast, may be used in the statistical analysis. 
8.5.1.3. Criteria for Handling Concentration Below the Limit of Quantification or 
Missing Concentrations for Pharmacokinetic Analysis 
Plasma concentrations below the limit of quantification (BLQ) will be assigned a value of 0 
before the first measurable concentration and thereafter BLQ concentrations will be treated as 
missing. The following rules apply to the specific situations defined below: 
● If an entire concentration-time profile is BLQ, it will be excluded from PK analysis. 
● Where 2 or more consecutive concentrations are BLQ at the end of a profile, the profile 
will be deemed to have terminated and any further quantifiable concentrations will be 
Page 15 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 15 of 21 
 
 
ST-AD-031 Version 02 
 
set to missing for the calculation of the PK parameters, unless they are considered to be 
a true characteristic of the profile of the drug. 
● If a predose plasma concentration is missing, it will be set to 0 by default within 
Phoenix WinNonlin. 
8.5.1.4. Treatment of Outliers in Pharmacokinetic Analysis 
If a value is considered to be anomalous due to being inconsistent with the expected PK 
profile, it may be appropriate to exclude the value from the PK analysis. However, the 
exclusion of any data must have strong justification and will be documented in the CSR. 
Any quantifiable predose concentration value in the first treatment period will be considered 
anomalous and set to missing for the PK analysis. This will be set to 0 by default in Phoenix 
WinNonlin. 
If the predose concentration is >5% of Cmax in the second treatment period, all PK 
concentration and parameter data will be excluded from the summary statistics and statistical 
analysis for that period. 
8.5.2.  Presentation of Pharmacokinetic Data 
All PK concentrations and parameters will be listed.  
Summary tables, arithmetic mean (+ standard deviation [SD]) figures, overlaying individual 
figures, and individual figures by treatment and time postdose will be provided for plasma 
PK concentrations. All figures will be produced on both linear-linear and linear-logarithmic 
scales, with the exception of figures across all days, which will be produced on the 
linear-linear scale only. The +SD bars will only be displayed on the linear-linear scale.  
Summary tables by treatment will be provided for all PK parameters, with the exception of 
diagnostic regression-related PK parameters. Separate summary tables by treatment and time 
interval will be provided for excretion parameters and cumulative excretion parameters.  
A subject may be excluded from the PK summary statistics and statistical analysis if the 
subject has an AE of vomiting that occurs at or before 2 times the median tmax.   
If the actual time of sample collection deviates from the nominal time by more than ±10%, 
the concentration will be flagged, but included in the summary statistics. 
Individual concentrations deemed to be anomalous will be flagged in the listings and 
excluded from the summary statistics. 
For plasma concentration data the following rules will apply: 
● Values that are BLQ will be set to 0 for the calculation of summary statistics. 
● Arithmetic mean or median values that are BLQ will be presented as 0. 
Page 16 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 16 of 21 
 
 
ST-AD-031 Version 02 
 
For PK parameters the following rule will apply: 
● Geometric mean and coefficient of variation will not be calculated for tlast, tmax. 
8.5.3. Pharmacokinetic Statistical Methodology  
A statistical analysis will be conducted to investigate the drug-drug interaction, the primary 
PK parameters will be AUCinf, AUC0-tlast, and Cmax for sotorasib on each of the dosing days. 
All other PK parameters will be regarded as secondary and will not be subject to inferential 
statistical analysis.  
A linear mixed effects model will be used to analyze log-transformed primary PK parameters. 
The model will assume fixed effect for treatment and a random effect for subject. Geometric 
mean ratios for Cmax and AUC values and associated 90% confidence intervals 
(Test/Reference) will be estimated. The “Reference” treatment for PK analysis will be 
sotorasib administered alone with water, while the “Test” treatment will be omeprazole 
administered in combination with sotorasib and an acidic beverage. 
For each PK parameter separately, the least squares mean (LSM) for each treatment, 
difference in LSMs between the test and reference treatments, and corresponding 90% 
confidence interval (CI) will be calculated; these values will then be back-transformed to give 
the geometric least squares mean (GLSM), ratio of GLSMs, and corresponding 90% CI.  
Additionally, the pooled estimate (across all treatments) of the within-subject CV will be 
calculated, and residual plots will be produced to assess the adequacy of the model(s) fitted.  
Examples of the SAS code that will be used are as follows: 
Mixed Model Analysis  
proc mixed data = <data in>; 
  by parcat1n parcat1 pkday paramn param; 
  class trtan usubjid; 
  model l_pk = trtan aperiod trtseqp / cl residual ddfm = kr; 
  lsmeans trtan / cl pdiff = control('1') alpha = 0.1; 
  random intercept / subject = usubjid(trtseqp);  
  ods output lsmeans = <data out>;   
  ods output diffs = <data out>; 
  ods output covparms = <data out>; 
run; 
8.6. Safety and Tolerability Assessments  
8.6.1. Adverse Events  
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
Version 25.0. (or higher if a new version is issued during the study; see the DMP for more 
details).  
A treatment-emergent adverse event (TEAE) will be defined as an AE that starts during or 
after the first dose, or starts prior to the first dose and increases in severity after the first dose.  
Page 17 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 17 of 21 
 
 
ST-AD-031 Version 02 
 
A treatment related TEAE will be defined as a TEAE with a relationship of possibly related 
or related to the study treatment, as determined by the investigator. 
All AEs will be listed. In addition to the data recorded in the database, the listings will 
include derived onset time and duration. Onset time will be calculated from the time of 
dosing for TEAEs only.  
The frequency of subjects with TEAEs and the number of TEAEs will be summarized for the 
following categories:  
● TEAEs (overall, serious, leading to discontinuation, and leading to death) by treatment  
● TEAEs by severity and treatment  
● Treatment-related TEAEs (overall, serious, leading to discontinuation, and leading to 
death) by treatment  
● Treatment-related TEAEs by severity and treatment  
The frequency of subjects will be summarized separately for TEAEs and treatment-related 
TEAEs by the following:  
● System organ class, preferred term, severity and treatment  
● Preferred term, severity and treatment  
For the AE data the following rules will apply:  
● For the derivation of TEAE status: If the start date/time of an AE is incomplete or 
missing, an AE will be assumed to be a TEAE, unless the incomplete start date/time or 
the end date/time indicates an AE started prior to the first dose.  
● For the derivation of treatment-related TEAE status: If the study treatment relationship 
for a TEAE is missing, a TEAE will be assumed to be a treatment-related TEAE.  
● For the derivation of onset time (applicable to TEAEs only): If the start date/time of a 
TEAE is missing, onset time will not be calculated. If the start date/time of a TEAE is 
incomplete, where possible, the minimum possible onset time will be calculated and 
presented in ‘≥DD:HH:MM’ format (eg, if the date/time of the last associated dose is 
01MAY2019/08:00 and recorded start date/time of a TEAE is 03MAY2019, then the 
minimum possible onset time will be calculated by assuming a TEAE started at the first 
hour and minute of 03MAY2019 [03MAY2019/00:00], thus will be presented as onset 
time ≥01:16:00 in the listing). If the start date of a TEAE is the same as the date of the 
last associated dose but the start time of a TEAE is missing, an onset time will be 
presented as ‘≥00:00:01’. Any clock changes will be accounted for in the derivation.  
● For the derivation of duration (applicable to all AEs): If the end date/time of an AE is 
missing, duration will not be calculated. If the start or end date/time of an AE is 
Page 18 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 18 of 21 
 
 
ST-AD-031 Version 02 
 
incomplete, where possible, the maximum possible duration will be calculated and 
presented in ‘≤DD:HH:MM’ format (eg, if the start of an AE date/time is 
01MAY2019/08:00 and its recorded end date/time is 03MAY2019, then the maximum 
possible duration will be calculated by assuming an AE ended at the last hour and 
minute of 03MAY2019 [03MAY2019/23:59], thus will be presented as 
duration ≤02:15:59 in the listing). Any clock changes will be accounted for in the 
derivation.  
● For the calculation of TEAE summary statistics: If the severity of a TEAE is missing, 
that TEAE will be counted under the ‘missing’ category. 
● For the calculation of TEAE summary statistics: If a subject experienced multiple 
TEAEs with the same preferred term for the same treatment, this will be counted as 1 
TEAE for that treatment under the maximum severity recorded.  
8.6.2. Clinical Laboratory Parameters  
All clinical laboratory parameters, their changes from baseline, and percentage changes from 
baseline will be listed, as applicable; any value outside the clinical reference range will be 
flagged. Separate listings will be provided for any parameter for which there is any individual 
subject value outside the respective clinical reference range.  
Summary tables by timepoint will be provided for clinical chemistry, hematology, and 
urinalysis parameters, with changes from baseline and percentage changes from baseline, as 
applicable. 
Values recorded as <x, ≤x, >x, or ≥x will be displayed in the listings as recorded. For the 
derivation of listing flags and calculation of summary statistics, <x and ≤x values will be set 
to 0, whereas >x and ≥x values will be set to x. 
8.6.3. Vital Signs Parameters  
All vital signs parameters, their changes from baseline, and percentage changes from 
baseline, will be listed, as applicable; any value outside the clinical reference range will be 
flagged.  
Summary tables by timepoint will be provided for all vital signs parameters, with changes 
from baseline and percentage changes from baseline, as applicable. 
8.6.4. 12-lead Electrocardiogram Parameters   
All 12-lead ECG parameters will be listed, as applicable; any value outside the clinical 
reference range will be flagged.   
Summary tables by timepoint will be provided for all 12-lead ECG parameters. 
Page 19 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 19 of 21 
 
 
ST-AD-031 Version 02 
 
An outlier analysis will be performed for QT interval corrected for heart rate using 
Fridericia’s formula (QTcF). The analysis will include all individual original, repeat, and 
unscheduled postdose values.  
The maximum postdose values will be summarized by treatment according to the following 
categories:  
● ≤450 ms  
● >450 and ≤480 ms (all instances flagged in the listing)  
● >480 and ≤500 ms (all instances flagged in the listing)  
● >500 ms (all instances flagged in the listing)  
The maximum increases from baseline will be summarized by treatment according to the 
following categories:  
● ≤30 ms  
● >30 and ≤60 ms (all instances flagged in the listing)  
● >60 ms (all instances flagged in the listing)  
8.6.5. Other Assessments  
Medical history will not be listed.   
All other safety and tolerability assessments not detailed in the above sections will be listed 
only.  
8.6.6. Safety and Tolerability Statistical Methodology  
No inferential statistical analyses are planned.  
9. INTERIM ANALYSES  
No formal interim analyses are planned for this study.  
10. SIGNIFICANT CHANGES FROM THE PROTOCOL-SPECIFIED ANALYSES  
There were no significant changes from the protocol-specified analyses.  
11. REFERENCES  
1. ICH. ICH Harmonised Tripartite Guideline: Structure and content of clinical study reports 
(E3). 30 November 1995.  
Page 20 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 20 of 21 
 
 
ST-AD-031 Version 02 
 
2. ICH. ICH Harmonised Tripartite Guideline: General considerations for clinical trials (E8). 
17 July 1997.  
3. ICH. ICH Harmonised Tripartite Guideline: Statistical principles for clinical trials (E9). 
5 February 1998.  
4. ICH. ICH Harmonised Tripartite Guideline: Addendum on estimands and sensitivity 
analysis in clinical trials to the guideline on statistical principles for clinical trials (E9 [R1]). 
20 November 2019  
Page 21 of 24


Statistical Analysis Plan 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
Final Version 1.0, 14 September 2022 
Page 21 of 21 
 
 
ST-AD-031 Version 02 
 
12. APPENDICES 
Appendix 1: 
Document History 
Status and Version 
Date of Change 
Summary/Reason for Changes 
Final Version 1.0 
NA 
NA; the first version. 
NA = not applicable 
 
Page 22 of 24


Page 23 of 24
Statistical Analysis Plan (SAP)/Initiation of 
Programming Approval Form 
Type of Approval (select one) : [8J SAP D Initiation of Programming 
-Sponsor Name: 
Sponsor Protocol/CIP ID: 
SAP text filename: 
Version: 
Covance Approval(s): 
Lead Statist1c1an 
Approval Signature 
Print Name 
Job Title 
Date 
Sponsor Approval(s): 
Amoen Inc. 
2 )220024 
AMG 
510_20220024_8493285 
_SAP _Final_14sept2022 
1 
Covanc 
8493285 
e Study 
ID: 
TFL 
AMG 
shells 
510_ 20220024_8493285_ 
filenam 
TFL 
e: 
shells final 14seot2022 
Date: 
9/20/2022 
By signing below when the statistical analysis plan {SAP) is considered final, the 
signatories agree to the analyses to be performed for this study and to the format of 
the associated tables, figures, and listings (TFLs). Once the SAP has been signed, 
programming of the Analysis Dataset Model (ADaM) datasets and TFLs based on these 
documents can proceed. Any modifications to the SAP text and TFL shells made after 
signing may result in a work-scope change. 
Approval Signature 
Print Name 
Job Title 
Date 
N/A 
Please scan/email comoleted form(s) to the Lead Statistician listed below: 
Printed Name/Title: 
Email: 


Clinical Study Report 
CONFIDENTIAL 
Labcorp Drug Development Study: 8493285 
Protocol Reference: 20220024 
  
16.1.9.2. 
Quality Tolerance Limit Definitions 
Parameter 
Justification for Parameter 
Unit Tolerance 
Minimum number of 
evaluable subjects 
needed. 
A shortfall in the overall number 
of subjects could have had a 
significant impact on 
interpretation of the primary 
endpoint because of 
limited/insufficient exposure. 
N: 14 
 
Final
Page 24 of 24